

FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome
Indirizzo di residenza

GIOVANNI BLANDINO

[REDACTED]

Indirizzo lavorativo

LABORATORIO DI ONCOGENOMICA ED EPIGENETICA
ISTITUTO NAZIONALE TUMORI REGINA ELENA
VIA ELIO CHIANESI, 53, 00144, ROMA

Telefono

+39 06 5266 2911 - 2972

Fax

+39 06 5266 2880

E-mail

giovanni.blandino@ifo.gov.it, [REDACTED]
[REDACTED]

Nazionalità

Italiana

Data di nascita

24/07/1965

ESPERIENZA LAVORATIVA

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Principali mansioni e responsabilità

2018-presente
Istituto Nazionale Tumori Regina Elena, Roma, Italia
Membro della Commissione Interna per le Sperimentazioni Cliniche (CISC)
Responsabile della ricerca traslazionale IRE
(delibera 291 del 23.04.2018)

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Principali mansioni e responsabilità

2017 - presente
Istituto Nazionale Tumori Regina Elena, Roma, Italia
Membro del Molecular Tumor Board IRE

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Principali mansioni e responsabilità

2016-presente
Istituto Nazionale Tumori Regina Elena, Roma, Italia
Direttore UOSD Oncogenomica ed Epigenetica

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Principali mansioni e responsabilità

2016-2018
Istituto Nazionale Tumori Regina Elena, Roma, Italia
Coordinatore del "Clinical Trials Office" IFO

• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	2008 - 2016 Istituto Nazionale Tumori Regina Elena, Roma, Italia Coordinatore delle attività di ricerca del Laboratorio di Oncogenomica Traslazionale, IRE
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	2007-2011 Istituto Nazionale Tumori Regina Elena, Roma, Italia Coordinatore Istituzionale per la Ricerca, Ufficio della Direzione Scientifica, IRE
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	2002-2016 Istituto Nazionale Tumori Regina Elena, Roma, Italia Dirigente Medico di I livello presso il Dipartimento di Oncologia Sperimentale, IRE
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	1999-2001 Istituto Nazionale Tumori Regina Elena, Roma, Italia Giovane Ricercatore Telethon, Laboratorio di Oncogenesi Molecolare, IRE
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	1993-1995 Istituto Nazionale Tumori Regina Elena, Roma, Italia Ricercatore Contrattista
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	1991-1993 Istituto Nazionale Tumori Regina Elena, Roma, Italia Ricercatore Borsista AIRC

ISTRUZIONE E FORMAZIONE

• Date (da – a) • Qualifica conseguita	2014-2021 Abitolazione al ruolo di Professore Ordinario di biologia molecolare
• Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Qualifica conseguita • Livello nella classificazione nazionale	1994 Università di Milano, Istituto Nazionale Tumori, Milano, Italia Specializzazione in Oncologia Medica cum laude Oncologo
• Date (da – a) • Qualifica conseguita	1990 Abitolazione professionale in Medicina e Chirurgia
• Date (da – a) • Nome e tipo di istituto di istruzione o formazione • Qualifica conseguita	1990 Università di Catania, Italia Laurea cum laude e proposta al Premio Bisceglie Medicina e Chirurgia

ATTIVITÀ SCIENTIFICA SVOLTA ALL'ESTERO

• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	Luglio 2019 Weizmann Institute of Science, Rehovot, Israele Ricercatore ospite
--	---

• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	Marzo 2012 – presente McMaster University, Hamilton, Canada Professore Clinico Associato (Associate Clinical Professor) "part-time", Dipartimento di Oncologia (https://healthsci.mcmaster.ca/oncology/about-us/directory) (allegato 5)
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	Settembre 2010 Ludwig Institute for Cancer, University of Oxford, Inghilterra Ricercatore ospite
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	Settembre 2005 Weizmann Institute of Science, Rehovot, Israele Ricercatore ospite presso il Dipartimento di Biologia Molecolare Cellulare
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	Giugno 2001 Mount Sinai Institute, New York, USA Ricercatore ospite presso il Dipartimento di Nefrologia
• Date (da – a) • Nome e indirizzo del datore di lavoro • Principali mansioni e responsabilità	1995-1999 Weizmann Institute of Science, Rehovot, Israele Ricercatore borsista presso il Dipartimento di Biologia Cellulare Molecolare
MAORELINGUA	Italiana
ALTRE LINGUE	Inglese
• Capacità di lettura • Capacità di scrittura • Capacità di espressione orale	eccellente eccellente eccellente
PATENTE	Patente B
CAPACITÀ E COMPETENZE TECNICHE	Comprovata esperienza nella pianificazione di progetti di ricerca traslazionale. Conoscenza delle principali metodiche di biologia molecolare e cellulare. Conoscenza delle tecnologie Omiche, in particolare: - piattaforma Agilent per lo studio dei profili di espressione dei microRNA per l'identificazione di nuovi biomarcatori tissutali e circolanti in diversi tipi di tumori; - piattaforma Affimetrix per lo studio dei profili di espressione dei trascritti in tessuti normali e tumorali; - piattaforma Illumina per il sequenziamento NGS per l'analisi del DNA genomico, del trascrittoma e dell'epigenoma di tessuti normali e tumorali (ChIPseq, RNAseq, smallRNAseq); - Risonanza Magnetica Nucleare (NMR) per l'analisi dei profili metabolici cellulari. Disegno ed implementazione di un pannello mutazionale per i geni più frequentemente mutati (TP53, FAT1, P16) nei tumori della testa e del collo per analisi delle mutazioni nei tessuti tumorali e nel DNA circolante.

**UOSD ONCOGENOMICA ED
EPIGENETICA**

Personale:

4 Dirigenti di I livello (2 Medici, 2 Biologi)

21 Ricercatori Sanitari

2 Collaboratori di ricerca

3 Tecnici

5 Borsisti

5 Tesisti

Anno	IFg	Target	N° pubblicazioni
2017	188.465	120	33
2018	192.530	167.892	29
2019	218.245	192	33

Impact Factor raggiunto negli ultimi 3 anni dalla UOSD. Target=obiettivo stabilito dalla direzione scientifica; IFg= impact factor prodotto dalla UOSD nell'anno indicato.

Anno	Atteso	Verificato
2017	910000 euro	1219884 euro
2018	950000 euro	1173192 euro

Capacità di attrazione dell'unità UOSD: finanziamenti da grant.

COLLABORAZIONI
(vedere allegato 6)

IRE:

UOC Chirurgia Senologica IRE
UOC Chirurgia Toracica IRE
UOC Ginecologia Oncologica IRE
UOC Chirurgia Epatobiliopancreatica IRE
UOC Neurochirurgia IRE
UOSD Chirurgia Digestiva IRE
UOC Otorinolaringoiatria e Chirurgia Cervico-Facciale IRE
UOC Anatomia Patologica IRE
UOC Oncologia Medica 2 IRE
UOC Oncologia Medica 1 IRE
UOC Radiologia IRE
UOC Radioterapia IRE
Biobanca Liquidi Biologici IRE
Biobanca biopsia Biologici IRE

ISG:

Direzione Scientifica ISG (vedi allegato 7)
UOSD Microbiologia e Virologia ISG
UOC Dermatologia Infettiva ISG

NAZIONALI:

Istituto Superiore di Sanità
Università "La Sapienza" di Roma
Università di Padova
Università di Trieste
Università di Milano
Università di Modena e Reggio Emilia
Humanitas Ospedale di Milano
IRCCS Ospedale San Raffaele di Milano
IRCCS Istituto Ortopedico Rizzoli di Bologna

INTERNAZIONALI:

Mc Master University, Hamilton, Canada.
Weizmann Institute of Science, Rehovot, Israele - delegato del DS per il progetto bilaterale IRE WIS (vedi lettera in allegato 8).
Princess Margaret Cancer Centre, Toronto, Canada.
Università di Chicago, IL, USA.
Peter MacCallum Cancer Centre, Melbourne, Australia.
Mount Sinai Institute, New York, USA.
Cancer Research Center di Lione, Francia.
Università di Medicina di Plovdiv, Bulgaria –delegato del DS nei rapporti bilaterali.
Medical School Università di Atene, Grecia.

	PRIVATI Eurofins Genoma (convenzione nazionale per lo sviluppo di kit- allegato 9) Genetechron
RICONOSCIMENTI	2020 membro del Molecular Tumor Board dello studio "The Rome trial from histology to target: the road to personalize target therapy and immunotherapy - Fondazione Medicina Personalizzata. (allegato 10) 2019 membro del direttivo della Società Italiana di Cancerologia (SIC). 2018 Co-Chair della piattaforma Biomarkers dell'Associazione A_IATRIS. 1999 Borsa di studio per Giovani Ricercatori con annesso grant per svolgere attività di ricerca del Telethon di rientro dall'estero. 1996 Borsa di Studio del Pogramma "Feinberg Postdoctoral Fellowship" del Weizmann Institute of Science. 1995 Borsa di studio AIRC per attività di ricerca di post-dottorato sa svolgere all'estero, presso il Weizmann Institute of Science di Israele. 1993 Borsa di studio per attività di ricerca post-laurea dell'Istituto Tumori Regina Elena di Roma. 1991 Borsa di studio AIRC per attività di ricerca di post-laurea da svolgere in una regione diversa da quella nella quale si è conseguita la laurea.
ORGANIZZAZIONI PROFESSIONALI (PASSATE E PRESENTI)	Membro Commissione di Valutazione: HSFP fellowship and Career Award; ISF-Israel National Foundation; BSF-Binational USA-Israel Foundation; CMRH-Netherland Cancer Research; MRC program; Austrian Cancer Society-Fellowship and Grant Program; Career Program (Associate Professorship) University of Singapore; Dutch Cancer Society; German-Israel Society, North West Cancer Research Fund, AICR, UICC Fellowship Program, Cancer Research UK, AFM-Genethon, Foundation for Polish Science, Bar-Ilan University, Tel-Aviv, Israel, Weizmann Institute of Science, Health Research Board (HRB) Ireland, UK Prostate Cancer, Dept. of Oncology, University of Oxford, Dept. of Oncology, McMaster University, Hamilton, Canada, ERA-NET TRANSCAN, EU-FP7, Health Research Council of New Zeland, Terry Fox Research Institute, Vancouver, Canada (Chair of the Reviewer Panel), Deutsche Forschungsgemeinschaft German Research Foundation, Wellcome trust/Indian Alliance FellowshipProgram; FNP prize; INSERM grant application.

**EDITORE E REVIEWER
PER RIVISTE SCIENTIFICHE**

Deputy Editor: Journal of Experimental and Clinical Cancer Research.

Receiving Editor: Cell Death and Disease.

Associate Editor: BMC Cancer, Exploration of Targeted Anti-tumor Therapy.

Membro del Board Editoriale: Precision Cancer Medicine, Cancers

Revisore per le seguenti riviste scientifiche:

Cell; Cancer Discovery; Physiological Reviews; Annals of Oncology; Molecular Cell; The EMBO Journal; EMBO Molecular Medicine; EMBO Reports; Cell Report; Nature Reviews Clinical Oncology; PNAS; Blood; Journal of the National Cancer Institute; PLOS Genetics; Molecular Cell Biology; Genome Biology; Cancer Research; Leukemia; EBioMedicine; Nature Communications; Oncogene; Nucleic Acid Research; Cell Death and Differentiation; Therapeutic Advance in Medical Oncology; BMC Medicine; Journal of Hepatology; Molecular Oncology; Aging Cell; Neurotherapeutics; Molecular Biology of Cell; Molecular Medicine; Cell Cycle; Molecular Therapy-Nucleic Acid; Clinical Epigenetics; Biochemical Pharmacology; BMC Molecular Biology; Theranostics; Journal of Cell Science; Cellular and Molecular Life Science (CMLS); Proteins; FEBS Letters; RNA Biology; Journal of Molecular Biology; Experimental Cell Research; British Journal of Pharmacology; Int. Journal of Cancer; Biochemical Journal; Scientific Reports; Cancer Letters; Carcinogenesis; Cellular Signaling; Acta Biochimica et Biophysica Sinica; Molecular Carcinogenesis; Archives Journal of Dermatology; European Journal of Cancer; Cell Proliferation; J. of Bone Oncology; The Open Cell Signaling Journal; Environmental Science and Technology Letters; Cell Tissue and Research; BBA; Int. J. of Biochem. Cell. Biol; Oncology; Tumor Biology; BMC Genomics; BMC Chemical Biology; Annals of Otolaryngology and Rhinology; Breast Cancer Research and Treatment; Cancer Therapeutics; PLoS One; Clinical Epigenetics; Liver International; Cellular Physiology and Biochemistry; Cell Death and Disease; Molecules; Cancer Biomarkers; Biochemistry and Biophysics Report; Journal of the American Aging Association; Human Mutation; Cell Communication and Signaling; Drug Design Development and Therapy; Cancer Biomarker; The Journal of Obstetrics and Gynecology Research; Clinical and Translational Medicine; International Journal of Biological Sciences; Current Pharmaceutical Biotechnology; Experimental Biology and Medicine; International Journal of Brain Disorder and Treatment; Marine Drugs; Journal of Cancer Research and Clinical Oncology; Computers in Biology and Medicine; Journal of Functional Food; Scandinavian Journal of Immunology; Endocrine Connections; Computational Biology and Chemistry; Biomedicine and Pharmacotherapy; Expert Opinion on Therapeutic Targets; Rheumatology and Therapy; Epigenomics; Cell Biology and Toxicology; Frontiers in Cell and Developmental Biology; Frontiers in Pharmacology; Frontiers in Molecular and Cellular Oncology; Medical Science Monitor; Molecular Diagnosis and Therapy; Expert Opinion on Drug Delivery;

Bioscience Reports; NeuroToxicology; Chemico-Biologic Interaction; Molecular Biology Reports; Molecular Therapy; Nucleic Acid.

Membro dell'esercizio di Valutazione della Qualità della Ricerca (VQR)
dell'Agenzia Nazionale di valutazione del sistema Universitario e della Ricerca (ANVUR).

ATTIVITA' DI INSEGNAMENTO

Insegnamento al corso di Biologia Molecolare in Oncologia (lectures) Università La Sapienza (Roma, Italia).

Insegnamento al corso sperimentale "Cell cycle and apoptosis", organizzato dalla Scuola Internazionale di Oncologia e Medicina Sperimentale (Roma 1-4 Dicembre, 1994).

Docente Scuola di Dottorato in Biochimica e Biologia Molecolare, Dip. Medicina Sperimentale, Università di Tor Vergata, Roma (dal 2018).

Attività di tutorship di dottorandi ed insegnamento presso il dipartimento di Oncologia e Medicina della Mc Master University (dal 2012).

ATTIVITA' DI TUTORE

Corso di Laurea relatore delle seguenti tesi selezionate:

1. Olimpia Monti, M.Sc., Università di "Tor Vergata", titolo della tesi: "p73, p63 and mutant p53: members of protein complexes floating in cancer cells", Roma, Italia, 2001- 2002
2. Sara Donzelli, M.Sc., Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Laurea Triennale in Scienze Biologiche, titolo della tesi: "Producing cancer cell lines expressing protein mutant p53", Roma, Italia, 2002-2005
3. Sara Donzelli, M.Sc., Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Laurea Specialistica in Biologia Applicata alla Ricerca Biomedica, titolo della tesi: "Oncogenomic Approaches in Exploring Gain of Function of Mutant p53", Roma, Italia, 2005-2007
4. Federica Ganci, M.Sc., Università di "Tor Vergata", titolo della tesi: "The mutant protein p53His175 controls miR.128b expression in a human large-cell lung cancer cell line", Roma, Italia, 2007- 2008
5. Jlenia Vitale, Università degli studi di Trieste, titolo della tesi: "New insights in circular RNA functions: CIRCPVT1 regulation and oncogenic role in head and neck squamous cell carcinomas", Trieste, Italia, 2016-2017
6. Chiara Turco, M.Sc., Università di Roma "La Sapienza" titolo della tesi: "Characterization of the interaction between gain of function mutant p53 proteins and PI3K pathway in HNSCC" Roma, Italia, 2017-2018.
7. Giulia Orlandi, M.Sc., Università di "Tor Vergata", titolo della tesi: "Ricerca di miRNA circolanti come biomarcatori predittivi e di diagnosi per lo sviluppo della mucosite indotta da trattamento antitumorale", Roma, Italia, 2019-2020
8. Simone Falco, M.Sc., Università di Lund, titolo della tesi: "Exploring non-coding factors in cancer metastases", Lund, Svezia, 2019-2020
9. Alina Palcau, M.Sc., Università di Roma "La Sapienza" titolo della tesi: "Circ-PVT1 as non coding mediator of breast cancer metabolism", Roma, Italia, 2019-2020
10. Claudia Catulli, M.Sc., Università di "Tor Vergata", titolo della tesi: "Ruolo oncosoppressore del miR-376a-3p nel tumore della testa e del collo", Roma, Italia, 2019-2020

Dottorato di Ricerca relatore delle seguenti tesi selezionate:

1. Olimpia Monti, M.Sc., Università di "Tor Vergata", Ph.D, titolo della tesi: "The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs", Roma, Italy, 2003- 2006

2. Eleonora Lapi, M.Sc., Università di "Tor Vergata", Ph.D in Biologia Molecolare Cellulare, titolo della tesi: "Identification of novel and direct target genes of p73", Roma, Italia, 2004- 2007
3. Stefania Dell'Orso, M.Sc., Ph.D in Endocrinologia e Medicina Molecolare, Facoltà di Medicina, Università di Roma "La Sapienza", titolo della tesi: "Application of ChIP on chip analysis to the identification of mutant p53 target genes", Roma, Italia, 2006-2009
4. Francesca Fausti, Ph.D in Endocrinologia e Medicina Molecolare, titolo della tesi: "Role of YAP in apoptosis and senescence processes", Roma, Italia, 2006-2009
5. Francesca Biagioni, M.Sc., Università di Roma "La Sapienza", Ph.D in Biologia e Medicina Molecolare, Ph.D in Scienze Immunologiche, titolo della tesi: "The advent of microRNAs in the molecular taxonomy of breast cancer", Roma, Italia, 2006-2009
6. Efrem Bertini, M.Sc., Università di "Tor Vergata", Ph.D in Biochimica e Biologia Molecolare, titolo della tesi: "Yap is regulated by phosphorylation at the G2/M transition", Roma, Italia, 2006- 2009
7. Fabio Valenti, M.Sc., "Università di Messina", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Neuroscienze, Medicine School University di Messina, titolo della tesi : "Peptide targeted therapies for the treatment of human cancers with mutations of the p53 gene", Messina, Italia, 2006-2010
8. Sara Donzelli, M.Sc., Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Genetica e Biologia Molecolare, titolo della tesi: "Study of mutant p53 protein gain of function by microRNAs modulation", Roma, Italia, 2007-2011
9. Sergio Galanti, M.Sc., Università di Roma "La Sapienza", Facoltà di Biologia e Biotecnologia "Charles Darwin", Ph.D in Biologia Cellulare e dello Sviluppo, titolo della tesi: "Identification of VDR transcriptional signatures in breast cancer cells by ChIP-on-chip analysis", Roma, Italia, 2008-2011
10. Federica Ganci, Università di Tor Vergata, Ph.D in Biologia Cellulare e Molecolare, titolo della tesi : "microRNAs expression profiling in HNSCC and their correlation with TP53 status", Roma, Italia, 2008-2011
11. Claudio Pulito, Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Genetica e Biologia Molecolare, titolo della tesi: MicroRNA-mediated anticancer effect of Metformin", Roma, Italia, 2013-2016
12. Tania Frixa, Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Genetica e Biologia Molecolare, titolo della tesi: "MicroRNA-128-2 induces global microRNAs down-regulation through Drosha and Dicer depletion, promoting lung cancer cells oncogenic potential", Roma, Italia, 2014-2017
13. Valeria Canu, Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Genetica e Biologia Molecolare, titolo della tesi: "MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer", Rome, Italia, 2014-2017
14. Maria Ferraiuolo, Università di Roma "La Sapienza", Facoltà di Matematica, Fisica e Scienze Naturali, Ph.D in Medicina Molecolare, titolo della tesi: "Agave negatively regulates YAP and TAZ transcriptionally and post-transcriptionally in osteosarcoma cell lines", Rome, Italia, 2016-2017

Supervisore esterno di commissioni di dottorato nazionali ed internazionali selezionate:

1. Raffaella Santoro, Ph.D in Oncologia Molecolare, titolo della tesi: "The Histone Acetyl Transferase Tip60 regulates the proapoptotic activities of the transcription factor E2F1", University of Southern Denmark, Odense, Denmark 2008 (Opponent).
2. Ying Zhao, Ph.D, titolo della tesi: "Pharmacological Targeting of p53 Pathway Alterations in Tumors", Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).
3. Jinfeng Shen, Ph.D, titolo della tesi: "Rescue of mutant p53 family members by the low molecular weight compound PRIMA-1MET/APR-246", Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).
4. Marco Napoli, Ph.D in Biomedicina Molecolare, titolo della tesi : "A Pin1/mutant p53 axis promotes aggressiveness in breast cancer", Università degli Studi di Trieste, Trieste, Italia 2010 (Opponent).
5. Erica Lorenzetto, PhD in Scienze Biomediche e Biotecnologiche, titolo della tesi: "Defining the role of YAP1 in 11q22-Amplified Cancer cell lines", Università degli Studi di Udine, Udine, Italia 2013 (opponent).
6. Sara Sessa, PhD in Scienze Biomediche e Biotecnologiche, titolo della tesi: "A "twist box" code of p53 inactivation in sarcomas", Università degli Studi di Udine, Udine, Italia 2013 (opponent).
7. Ilaria Castiglioni, PhD in Scienze Biomolecolari, titolo della tesi: "Development of drug screening assays for identification of new molecules against pancreatic ductal carcinoma", Università degli Studi di Trento, Trento, Italia, 2014 (opponent).
8. Giovanni Sorrentino, PhD in Biomedicina Molecolare, titolo della tesi: "Metabolic control of YAP and TAZ by the mevalonate pathway", Università degli Studi di Trieste, Italia, 2014 (opponent).
9. Kamil Lisek, PhD in in Biomedicina Molecolare, titolo della tesi: "Activation of the proteasome machinery by NRF2/mutant p53 axis and its therapeutic implications for triple negative breast cancer", Università degli Studi di Trieste, Italia, 2015.
10. Eleonora Ingallina, PhD in in Biomedicina Molecolare, titolo della tesi: "Identification of mutant p53 inhibitors by high-content screening", Università degli Studi di Trieste, Italia, 2015.
11. Carolanne Doherty, PhD in System Biology in Medicine, titolo della tesi: "Characterisation of Yes-associated protein 1 signalling networks, biochemical and biological functions", University College Dublin, external examiner, Dublin, June 2015.
12. Mahrou Vahabi, PhD, titolo della tesi: "miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells" School of Biology, College of Science, University of Tehran, Tehran, Iran, 2018.
13. Marco Fantuz, PhD in Biologia Molecolare, titolo della tesi: "Alterations of the secretory pathway induced by missense p53 mutants", Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italia, Aprile 2020

**ORGANIZZAZIONE
DI MEETING INTERNAZIONALI**

- 1) Making decisions in G1, Frascati, Italia 2002. Comitato Organizzatore: Alemà (CNR) Blandino (IRE) Cesareni (Univ Tor Vergata, Roma) Segatto (IRE)
- 2) 1st International p73/p53 Workshop, Roma, Italia 2002. Comitato Organizzatore: Levvero (Univ. La Sapienza), Melino (Univ. Tor Vergata), Blandino (IRE)
- 3) 2nd International p73/p53 Workshop, Roma, Italia 2004. Comitato Organizzatore: Levvero (Univ. La Sapienza), Melino (Univ. Tor Vergata), Blandino (IRE)
- 4) P53 Marathon, Ein Gedi, Israel, 2005. Comitato Organizzatore: Oren (Weizmann Institute of Science), Rotter (Weizmann Institute of Science), Wiman (Karolinska Institut), Blandino (IRE), Hainaut (IARC)
- 5) 3rd International p73/p53 Workshop, Roma, Italia 2007. Comitato Organizzatore: Levvero (Univ. La Sapienza), Melino (Univ. Tor Vergata), Blandino (IRE)
- 6) P53 Marathon, Lyon, France 2007. Comitato Organizzatore: Oren (Weizmann Institute of Science), Rotter (Weizmann Institute of Science), Wiman (Karolinska Institut), Blandino (IRE), Hainaut (IARC)
- 7) P53 Marathon, Acre, Israel 2009. Comitato Organizzatore: Oren (Weizmann Institute of Science), Rotter (Weizmann Institute of Science), Wiman (Karolinska Institut), Blandino (IRE), Hainaut (IARC)
- 8) The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Roma, Italia 22-23 Aprile, 2009. Published: Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. *Sci Signal*. 2009 Nov 3;2(95):mr6.
- 9) The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Aniccia (Roma), Italia, 2-5 November 2010. Published: McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y. Gli atti del congresso sono stati pubblicati come "Meeting Report "The Hippo tumor suppressor pathway: a report on "The Second Workshop On The Hippo tumor suppressor pathway". *Cell Death Differ*. 2011 Aug;18(8):1388-90.
- 10) 5th Mutant p53 Workshop: "From bench to bedside across mouse models", Aniccia (Roma), Italia, 24th May, 2011. Published: Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Gli atti del congresso sono stati pubblicati come "Meeting Report" "Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop". *Cell Death Differ*. 2012 Jan;19(1):180-3.
- 11) Keystone Symposium "The HIPPO Tumor Suppressor Network: from organ size control to stem cells and cancer", Monterey, CA, USA 19-23 May 2013 (Organizzatori: Dr. Sudol, Dr. Blandino, Dr. Halder, Dr. McNeil, Dr. Strano).
- 12) The HIPPO Pathway in Cancer. Roma, Italia. 15 Aprile, 2014 (Organizzatori: Dr. Blandino, Dr. Fanciulli and Dr.ssa Strano). (vedere lettere Prof. Sudol e Prof. Guan)
- 13) International Workshop on Metabolism, Diet and Chronic Disease: the perspective of cancer and cardiovascular disease prevention. Roma, Italia. 23 Giugno, 2014 (Organizzatori: Dr. Blandino, Dr.ssa Muli and Dr. Levvero).
- 14) The Epigen Workshop: Have OMICs approaches improved cancer deciphering and management? Roma, Italia 27 Ottobre, 2015 (organizzatore: Dr. Blandino)
- 15) 18th International p53 Workshop, Rehovot, Israel, Maggio 2020 (membro del comitato organizzatore internazionale).

FINANZIAMENTI

Responsabile del Progetto di Ricerca (sono stati selezionati i più rappresentativi)

"Study of MYC and YAP contribution to mutant p53 transcriptional activity in head and neck squamous cell carcinomas" Euro 786.000. Finanziato da AIRC 2018-2023

"Analisi mutazionale della porzione codificante dei geni TP53 e PIK3CA allo scopo di definire una terapia personalizzata per il tumore testa/collo basata sull'individuazione di specifiche mutazioni (farmacogenetica)" Euro 149.887. Finanziato da Lazio Innova (Regione Lazio) 2019-2021

"Identification of novel coding and non-coding transcriptional targets of gain of function mutant p53" Euro 440.000. Finanziato da AIRC 2014-2016

"Study of mutant p53-dependent epigenetic modifications in HNSCC" Euro 300.000. Finanziato dal MIUR e dal CNR, 2013-2016.

"Epigenetic and metabolic alterations in cancer pathogenesis" Euro 400.000 Finanziato dal MIUR-FIRB 2011-2014

"Profile of microRNA expression and CpG Island methylation in tissue samples from mesothelioma patients" Euro 600.000. Finanziato da INAIL 2010-2012

Unione Europea 6th Framework (FP6) "Integrated Project Activep53, PI e Coordinatore del consorzio Activep53: Euro 6.000.000.000 2004-2009 (prolungato fino al 2012).

"Exploring transcriptional activity of gain of function Mutant p53 protein"; Euro 330.000. Finanziato da AIRC 2007-2011.

"Linking transcriptome to proteome: Functional oncogenomics for diagnosis and treatment of human cancer" Coordinatore Scientifico della Piattaforma Oncogenomica multiistituzionale ROC finanziata dall'Associazione Italiana per la Ricerca sul Cancro. Euro 3.000.000 2004-2011.

Co-responsabile del Progetto di Ricerca (sono stati selezionati i più rappresentativi)

"Metastatic disease: the key unmet need in oncology - Second Edition" Euro 619.799. Finanziato da AIRC 5x1000 2019-2026.

"Targeting the abnormal MicroRNA and Splicing Signatures in HIV-associated cancers". Euro 600.000 Finanziato dal Concilio Sudafricano della Ricerca Medica (SAMRC) 2016.

"Global epigenomic profiling of normal and diseased cells for the diagnosis of normal and diseased cells for diagnosis of hematological malignancies" Euro 120.000 Finanziato dal Ministero della Salute 2010-

**STUDI CLINICI APPROVATI DAL
COMITATO ETICO IRE**

Titolo	Patologia	Promotore	Esito valutazione CEI	Pazienti arruolati
Un protocollo MASTER per realizzare studi di oncologia di precisione e meccanismologia nei tumori della mammella - METAMECH -	Tumore Mammella	IFOM – Istituto di FIRC di Oncologia Molecolare	Favorevole del 31/03/2020	65
MetOrg: Creazione di una biobanca di organoidi da tumori alla mammella metastatici (WP2 task 2.2 del progetto Metastatic disease: the key unmet need in oncology)	Tumore Mammella	Un. degli studi di Padova	Favorevole del 22/10/2019	65
Identificazione di nuovi biomarcatori circolanti per la cachessia in pazienti affetti da tumori della testa e del collo trattati con radio-chemioterapia	Tumore Testa-Collo	IRE	Favorevole del 01/10/2019	10
Ricerca sugli effetti della Autoguarigione Tantrica NgaiSo sulla Espressione di MicroRNA nel Siero, sulla Lunghezza del Telomero e sulla Attività Telomerasica in VOLONTARIE	Tumore Mammella	McMaster University/ Università di Milano	Favorevole del 14/03/2017	60
Studio del contributo delle proteine MYC e YAP all'attività trascrizionale di p53 mutata nei tumori testa-collo	Tumore Testa-Collo	IRE	Favorevole del 18/10/2016	43
Analisi differenziale dei profili di espressione dei microRNA in colangiocarcinoma, epatocarcinoma e metastasi epatiche	Tumore Gastrico-Epatico-Vie Biliari	IRE	Favorevole del 14/10/2014	240
Studio della correlazione tra profilo di espressione di microRNA e decorso clinico in pazienti affetti da carcinomi squamosi della testa e del collo	Tumore Testa-Collo	IRE	Favorevole del 26/11/2013	280
Analisi dei profili di espressione trascrizionale e dei microRNA in metastasi cerebrali da tumori primari di varia origine	Piu' patologie/metastasi	IRE	Favorevole del 25/11/2011	49

**STUDI CLINICI IN EQUIPE
APPROVATI DAL COMITATO
ETICO IRE**

Titolo	Patologia	Promotore	Esito valutazione CEI	Pazienti arruolati
Valutazione della sequenza ottimale di trattamento nelle pazienti affette da carcinoma mammario avanzato HER2 positivo pretrattate con Pertuzumab. Lo studio STEP	Tumore della mammella	IRE Laura Pizzuti	Favorevole del 26/02/2020	2
Glioma: aspetti biomolecolari del tessuto alla Radiomica	Glioma	IRE Veronica Villani	Favorevole del 07/11/2019	10
Validazione del Mitomic Test nello screening del tumore della prostata	Tumore della prostata	IRE Giuseppe Simone	Favorevole del 20/11/2018	171
Analisi dei profili di espressione dei microRNA e genotipizzazione del papillomavirus umano in una casistica retrospettiva di melanoma vulvare	Melanoma vulvare	IRE Mariantonia Carosi	Favorevole del 24/07/2018	10

Contributo allo studio clinicopatologico e molecolare dei Tumori epiteliali timici (TET) sulla base del Database internazionale ITMIG	Timoma/tumori del timo/TET	IRE Mirella Marino	Favorevole del 09/05/2017	12
MicroRNAs e DNA tumorale (ctDNA) circolanti come nuovi bio-marcatore non invasivi nel linfoma diffuso a grandi cellule B	Linfoma	IRE Francesco Marchesi	Favorevole del 12/07/2016	87

STUDI CLINICI SUL COVID

Titolo	Patologia	Promotore	Esito valutazione CEI	Partecipanti arruolati
Screening sierologico sulla prevalenza di anticorpi anti- sars-cov-2 in una popolazione isolana potenzialmente resistente alla diffusione del virus	Covid	Università di Milano	Favorevole del 25/04/2020 (allegato 11)	700
Caratterizzazione della diffusione del SARS-Cov-2: Screening sierologico Popolazione Sociale Roma Termini Binario 95	Covid	IFO	Favorevole del 26/05/2020 (allegato 12)	70
Gli ambulatori di strada e per strada: una strategia operativa per il contenimento del contagio da COVID nella popolazione immigrata fragile di Roma città metropolitana	Covid	IFO	Sottomesso al comitato etico dello spalanzani il 14/06/20	1000

**BREVETTI
NAZIONALI ED INTERNAZIONALI**

1. Inventori: Giovanni Blandino, Gennaro Citro, Rossella Maria Galati, Alessandra Verdina.

Numero e data di depositi in Italia: MI2004A002227, 19 November 2004

"This invention allows "Peptides to be able to break 53/p53, m-p53/p73 and m-p53/respective isoform proteins complex formed in the tumor cells and there uses in the pharmacological field". In addition, this invention uses a method that provokes the disruption of complex proteins found in the cancer cell lines in vitro. Furthermore, these peptides are used in preparing anti-cancer medicine"
Iter: 2007 Deposited permit request on a National/European level + permit requested in Israel, Singapore, the USA and EU. 2008 permit request made in Germany. 2010 Entered PCT national phase in the USA. 2011 Granted the PCT process in Japan.

2. Inventori: Giovanni Blandino, Gennaro Citro, Sabrina Strano, Silvia Di Agostino.

Numero e data di deposito in Italia: RM 2009A232 del 11/05/2009.

"The present invention concerns peptide able to disrupt the protein complex between HIS273 mutated p53 protein and oncosuppressive p73 protein in tumor cells and uses hereof in medical field. More particularly, the present invention concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to disrupt the protein complexes within tumor cells resulting from m-p53 and p73 proteins selectively in tumors wherein m-p53 contains HIS273 mutation. Iter: 2010 deposited international permit request"

3. Inventori: Giovanni Blandino, Sabrina Strano, Aboca management

"New active principles for the treatment of tumors". WO 2019/171268 A1.

12 Settembre 2019.

**PUBBLICAZIONI
SU RIVISTE SCIENTIFICHE**

H-index= 50 (calcolato con Scopus), 9227 citazioni totali

1) Callari D, Gasso G, Blandino G, Billitteri A. Azione del retinolo su colture di hepatoma H4. Boll. Soc. It. Biol. Sper. N11., 1989.

2) Callari D, Blandino G, Saccone V, D'Amico C, Billitteri A. Azione del retinolo sul recupero di cellule vitali e sul potenziale clonogenico di cellule HTC ipertemizzate in vitro. Boll. Soc. It. Biol. Sper. N.12, 1992.

3) Callari D, Blandino G, Saccone V, D'Amico C, Billitteri A. Azione dell'ipertermia e del trattamento con retinolo in vitro sull'adesività alla laminina ed alla fibronectina delle cellule HTC. Boll. Soc. It. Biol. Sper. N.12; 1992.

4) Callari D, Strano S, Blandino G, Saccone V, and Billitteri A. Adhesion to some extracellular matrix components of heat-treated HTC hepatoma cells. J. Exp. Clin. Cancer Res. 13; 2, 1994.

5) Strano S, Callari D, Billitteri A, and Blandino G. Fibronectin and Vitronectin Adhesion enhancement during U937 cells differentiation induced by IL-6 and LIF. J. Exp. Clin. Cancer Res., 13, 4, 1994.

6) Soddu S, Blandino G, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, and Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood, 83, 8, 1994.

7) Strano S, and Blandino G. Apoptosis: cell death or suicide. This is the problem! J. Exp. Clin. Cancer Res., 14, 3, 1995.

8) Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, and Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene, 10, 731-737, 1995.

9) Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, and Sacchi A. WT-p53 induces diverse effects in 32D cells expressing different

oncogenes. *Molecular and Cellular Biology*, 16, 2, 487-495, 1996. (The two first authors contributed equally to this work).

10) Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, and Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. *The Journal of Cell Biology*, 134, 1, 193-204, 1996.

11) Martinelli R, Blandino G, Scardigli R, Crescenzi M, Lombardi D, Sacchi A, and Soddu S. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. *Oncogene* 15, 607-611, 1997.

12) Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsterdam A, Yayon A, and Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. *Oncogene* 15, 2717-2725, 1997.

13) Scardigli R, Bossi G, Blandino G, Crescenzi M, Soddu S, and Sacchi A. Exogenous wt-p53 overexpression does not affect normal hematopoiesis: basis for bone marrow purging? *Gene Therapy* 4, 1371-1378, 1997.

14) Blandino G, and Strano S. Bcl-2: the pendulum of the cell fate. *J. Exp. Clin. Cancer. Res.*, 16, 1, 1997.

15) Rizzo M.G, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, Blandino G, Giuliaci S, Ferrari S, Soddu S and Sacchi A. Wtp53-action in human leukemia cell lines corresponding to different stages of differentiation. *British Journal of Cancer* 77, 1429-1438, 1998.

16) Wang Y, Blandino G, Oren M, and Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differently modifies the cytotoxicity of anticancer drugs. *Oncogene* 17, 1923-1930, 1998.

17) Blandino G, Levine AJ, and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. *Oncogene* 18, 477-485, 1999.

18) Wang Y, Blandino G, and Givol D. Induced p21 waf1 expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. *Oncogene* 18, 2643-2649, 1999.

19) Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73 α and their collaboration to induce apoptosis. *Nature* 399, 809-813, 1999.

20) Cerone M.A, Marchetti A, Bossi G, Blandino G, Sacchi A, and Soddu S. p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblast. *Cell Death and Differentiation* 7, 506-508, 2000.

21) Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine A.J, Sacchi A, Cesareni G, Oren M and Blandino G. Physical and functional interaction between p53 mutants and different isoforms of p73. *J. Biol. Chem.* 275, 29503-29512, 2000.

22) Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A and Blandino G. From p63 to p53 across p73. *FEBS Letters*, 490, 163-170, 2001.

23) Strano S, Munarriz E, Rossi M, Cristofanelli B, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G. Physical interaction with Yes-associated protein (YAP) enhances p73 transcriptional activity. *J. Biol.Chem.*, 276, 15164-15173, 2001.

- 24) Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, and Blandino G. The transcriptional repressor ZEB regulates p73 expression at the cross-road between proliferation and differentiation. *Mol. Cell Biol.*, 24, 8461-8470, 2001.
- 25) Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, and Leviero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. *Mol. Cell*, 9, 175-186, 2002.
- 26) Le Bras M, Delattre V, Bensaad K, Blandino G, and Soussi T. Monoclonal antibodies raised against Xenopus p53 interact with human p73. *Oncogene*, 14, 1304-1308, 2002.
- 27) Morena A.R, Riccioni S, Marchetti A, Tartaglia Polcini A, Mercurio A.M, Blandino G, Sacchi A, and Falcioni R. Expression of $\beta 4$ integrin subunit induces monocytic differentiation of 32D/v-Abl cells. *Blood*, 100, 96-106, 2002.
- 28) Strano S, Fontemaggi G, Costanzo A, Rizzo M.G, Monti O, Baccarini A, Del Sal G, Leviero M, Sacchi A, Oren M and Blandino G. Physical interaction with human tumor derived p53 mutants inhibits p53 activities. *J. Biol Chem.* 277, 18817-18826, 2002.
- 29) Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. *J. Biol Chem.* 277, 43359-43368, 2002.
- 30) Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, and Del Sal G. The Prolyl-Isomerase Pin1 reveals a new mechanism to control p53 functions following genotoxic insults. *Nature*, 419, 853-857, 2002.
- 31) Bensaad K, Le Bras M, Unsel K, Strano S, Blandino G, Tominaga O, Rouillard D and Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding and interfering with p73. *J. Biol. Chem.* 278, 10546-10555, 2003.
- 32) Strano S, and Blandino G. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53 proteins. *Cell Cycle* 2, 348-349, 2003.
- 33) Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C., Lavia P, and Leviero M. p73 is regulated by phosphorylation at the transition G2/M. *J. Biol. Chem.*, 278, 49196-49202, 2003.
- 34) Di Stefano V, Blandino G, Sacchi A, Soddu S, and G. D' Orazi. HIPK2 counteracts MDM2 inhibition of p53 by interfering with its ubiquitination and nuclear export. *Oncogene* 231, 5185-5192, 2004.
- 35) Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G, and Del Sal G. Pin1 links the activities of c-Abl and p300 in regulating p73 function. *Molecular Cell*, 14, 625-636, 2004.
- 36) Blandino G and M. Dobbelstein. p73 and p63-why do we still need them? *Cell Cycle* 3, 886-894, 2004.
- 37) Rizzo M.G, Giombini E, Diverio D, Vignetti M, Testa U, Sacchi A, Lo Coco F, and Blandino G. Analysis of p73 expression in acute myeloid leukemia: lack of DN-p73 expression is a frequent feature of acute promyelocytic leukemia. *Leukemia* 18, 1804-1809, 2004.

- 38) Dobbela M, Strano S, Roth J, and Blandino G. p73-induced apoptosis: a question of compartments and cooperation. *Biochem. Biophys. Res. Commun.* 331, 688-693, 2005.
- 39) Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, and Blandino G. The transcriptional co-activator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. *Molecular Cell.* 18, 447-459, 2005.
- 40) Fontemaggi G, Gurtner A, Damalas A, Higashi Y, Sacchi A, Strano S, Piaggio G and Blandino G. δ EF1 repressor controls selectively p53 family members during differentiation. *Oncogene.* Nov. 10; 24(49):7273-80, 2005.
- 41) Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, Blandino G, Taya Y, Lavie P. and Levrero M. p73 role in mitotic exit. *J. Biol. Chem.* 280, 30354-30360, 2005.
- 42) Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. *Oncogene* Jan 12 ; 25 (2):304-9, 2006.
- 43) Belloni L, Moretti F, Damalas A, Costanzo A, Blandino G, and Levrero M. Δ Np73 α protects myogenic cells from apoptosis. *Oncogene* Jun, 15 ;25 (25):3606-12, 2006.
- 44) Lapi E, Iovino A, Fontemaggi G, Soliera R, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G* and Strano S. S100A2 is a direct transcriptional target of p53 homologues during keratinocyte differentiation (*corresponding author) *Oncogene* Jun, 22 ;25 (26):3628-37, 2006.
- 45) Giombini E, Blandino G, Sacchi A, Lo Coco F, and Rizzo M.G. The complexity of p73 isoforms in human neoplasia. *Gene Ther. Mol. Biol.* 9:1-16, 2005.
- 46) Hoshino M, Qi M, Yoshimura M, Miyashita T., Tagawa K, Wada Y, Enokido Y, Marubuchi S, Harjes P, Arai N, Oyanagi K, Blandino G, Sudol M, Rich T, Kanazawa I, Wanker E.E, Salter M, and Okazawa H. Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. *J. Cell Biology* Feb. 589-604, 2006.
- 47) Di Agostino S, Strano S, Emiliozzi V, Sacchi A, Blandino G*, Piaggio G. Gain of function of mutant p53: the mutant p53/NFY protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. (*corresponding author) *Cancer Cell* Sep. 10 (3):191-202, 2006.
- 48) Strano S, Dell'Orso S, Mongioli A, Monti O, Lapi E, Di Agostino S, Fontemaggi G and Blandino G. Mutant p53 proteins: between loss and gain of function. *Head and Neck* 29:488-96, 2007.
- 49) Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, and Blandino G. Mutant p53: an oncogenic transcription factor. *Oncogene* 26:2212-9, 2007.
- 50) Weisz L, Damalas A, Lontos M, Karakaidos P, Fontemaggi G, Kalis M, Levrero M, Strano S, Gorgoulis W.G, Rotter V, Blandino G, Oren M. Mutant p53 enhances NF- κ B activation by tumor necrosis factor alpha in cancer cells. *Cancer Research* 67:2396-401, 2007.
- 51) Blandino G, Fanciulli M, Levrero M, Piaggio G. The Post Genomic Era: Workshop on Chromatin Immunoprecipitation related techniques. *Cell. Death and Diff.* 14:1390-1391, 2007.

- 52) Mainardi S, Palesscandolo E, Fontemaggi G, Diverio D, Grignani F, Testa U, Sacchi A, Lo Coco F, Leviero M, Blandino G* and Rizzo MG. DNP73 is a transcriptional target of PML/RAR oncogene (*corresponding author) *Cell Death and Differentiation* 14:1968-71, 2007.
- 53) Strano S, and Blandino G. YAP meets tumor suppression. *Mol. Cell*, 27:863-4, 2007.
- 54) Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. *Cancer Res.* May 15;68(10):3707-14, 2008.
- 55) Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G., Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. *Cell Cycle.* Jun 15;7(12):1870-9, 2008.
- 56) Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G. The disruption of the protein complex mutant p53/p73 increases selectively the response of tumor cells to anticancer drugs. *Cell Cycle.* Nov 1;7(21):3440-7, 2008.
- 57) Blandino G. Mitosis poisons p53. *Cell Cycle.* Nov 1;7(21), 2008.
- 58) Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. *Mol Cell.* Dec 26;32(6):803-14, 2008.
- 59) Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. *Curr Genomics.* May;9(3):200-7, 2008.
- 60) Benassi B, Strano S, Blandino G. Tetraploidy triggers mitochondria. *Cell Cycle.* May 1;8(9):1305-6, 2009.
- 61) Blandino G, Moll UM. p63 regulation by microRNAs. *Cell Cycle.* May;8(10):1466-7, 2009.
- 62) Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y. Promyelocytic leukemia protein is required for gain of function by mutant p53. *Cancer Res.* Jun 1;69(11):4818-26, 2009.
- 63) Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between transformation and tumor suppression. *Cell Cycle.* Jan 1;8(1):49-57, 2009.
- 64) Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, Mottolise M, Falcioni R. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. *Cancer Res.* Jul 15;69(14):5978-86, 2009.
- 65) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Blandino G. Metformin, diet and breast cancer: an avenue for chemoprevention. *Cell Cycle.* Aug 15;8(16):2661, 2009.
- 66) Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, Blandino G, Leviero M, Rizzo MG. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. *Oncogene.* Nov 12;28(45):4034-40, 2009.

- 67) Fontemaggi G, Dell'Orso S, Trisciuglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. *Nat Struct Mol Biol.* Oct;16(10):1086-93, 2009.
- 68) Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, Blandino G, Costanzo A, Sakaguchi K, Tuosto L. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. *Cell Cycle.* Oct 15;8(20):3396-405, 2009.
- 69) Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Maloni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. *J Exp Clin Cancer Res.* Oct 8;28:135, 2009.
- 70) Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. *Sci Signal.* Nov 3;2(95):mr6, 2009.
- 71) Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. *Cancer Cell.* Mar 16;17(3):273-85, 2010.
- 72) Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, Blandino G, Barresen-Dale A, Pipel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the abundance of microRNAs that restrain oncogenic transcription factors. *Sci. Signal.* Jun 1;3(124):ra43, 2010.
- 73) Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P and Ciliberto G. Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like targeting drugs. *Cell Cycle.* Jul 15;9(14):2678-87, 2010.
- 74) Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Floridi A, Passananti C, Blandino G, and Fanciulli M. Che-1 depletion inhibits mutant p53 expression and activates p73-dependent apoptosis by inducing endogenous DNA damage in human breast cancer. *Cancer Cell.* Aug 9;18(2):122-34, 2010.
- 75) Slee E, Benassi B, Goldin R, Zhong S, Blandino G, and Lu X. Phosphorylation of Ser312 contributes to tumour suppression by p53 in vivo. *Proc Natl Acad Sci U S A.* Nov 9;107(45):19479-84, 2010.
- 76) Santoro R, Blandino G. p53: The pivot between cell cycle arrest and senescence. *Cell Cycle.* Nov;9(21):4262-3, 2010.
- 77) Fontemaggi G, Dell'Orso S, Muti P, Blandino G and Strano S. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. *Cell Cycle.* Jun 15;9(12):2464-6, 2010.
- 78) Strano S and Blandino G. Stability strengths oncogenic activity. *Cell Cycle.* Apr 15;9(8):1458-9, 2010.
- 79) Goeman F, Blandino G. Novel insights into the cytoplasmic functions of p53. *Cell Cycle.* Jul 1;9(13):2498, 2010.
- 80) Dell'Orso S, Ganci F, Strano S, Blandino G, and Fontemaggi G. ID-4: a new player in the cancer arena. *Oncotarget.* May;1(1):48-58, 2010.

- 81) Di Agostino S, Strano S, Blandino G. YAP1 (Yes-associated protein 1, 65kDa). *Atlas Genet Cytogenet Oncol Haematol*. January 2010.
- 82) Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A, Leviero M, Strano S, Rotter V, Oren M and Blandino G. ChIP on chip analysis of in vivo mutantp53 binding to selected gene promoters. *OMICS*. May;15(5):305-12, 2011.
- 83) Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G, Blandino G, and Strano S. Omics underpins novel clues on VDR chemoprevention target in breastcancer. *OMICS*. Jun;15(6):337-46, 2011.
- 84) Ganci F, Conti S, Fontemaggi G, Manciooco V, Donzelli S, Covello R, Muti P, Strano S, Blandino G, Spriano G. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. *OMICS*. Jun;15(6):375-81, 2011.
- 85) Testoni B, Guerrieri F, Gerbal-Choine S, Blandino G and Leviero M. p53-paralog DNP73 oncogene is repressed by IFN α /STAT2 through the recruitment of the Ezh2 Polycomb Group transcriptional repressor. *Oncogene*. Jun 9;30(23):2670-8, 2011.
- 86) Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. *Int J Cancer*. Feb 15;130(4):921-9, 2011.
- 87) Testoni B, Voellenkle C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Leviero M. Chromatin dynamics of gene activation and repression in response to ifn(alpha) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. *J Biol Chem*. Jun 10;286(23):20217-27, 2011.
- 88) McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y. Meeting Report The Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo tumor suppressor pathway. *Cell Death Differ*. Aug;18(8):1388-90, 2011.
- 89) Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, Blandino G and Tuosto L. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. *J Biol Chem*. Nov 18;286(46):39693-702, 2011.
- 90) Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, Pesole G, Chimenti S, Guerrini L, Fanciulli M, Blandino G, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. *Proc Natl Acad Sci U S A*. Aug 16;108(33):13710-5, 2011.
- 91) Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessia D, Muti P, Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrc1, xrc3, gst paly a role in the risk of article developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. *BMC Cancer*. Jul 12;11:291, 2011.
- 92) Cioce M, Blandino G. PGC1 α Confers Specificity - Metabolic Stress and p53-Dependent Transcription. *Molecular Cell*. Nov 18;44(4):515-6, 2011.
- 93) Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. *Oncogene*. Jun 14;31(24):2931-42, 2012.
- 94) Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K and Oren M. Mutant p53 protein, master regulator of human malignancies:

a report on the fifth Mutant p53 Workshop. *Cell Death & Differentiation*. Jan;19(1):180-3, 2012.

95) Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Ciocce M. SASP mediates chemoresistance and tumor-initiating activity of Mesothelioma cells. *Oncogene*. Jun 28;31(26):3148-63, 2012.

96) Ciocce M, Canino C, Muti P, Strano S, Blandino G. Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. *Cell Cycle*. Jan 1;11(1):132-40, 2012.

97) Benassi B, Flavin R, Marchionni L, Pan Y, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, and Loda M. c-Myc is activated via USP2a-mediated modulation of microRNAs in prostate cancer. *Cancer Discov*. Mar;2(3):236-247 (co-corresponding author), 2012.

98) Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. microRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. *Cell Death and Differentiation* Jun;19(6):1038-48, 2012.

99) Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. Mutant p53 oncogenic functions are sustained by plk2 kinase through an autoregulatory feedback loop. *Cell Cycle*. Dec 15;10(24):4330-40, (co-corresponding author), 2012.

100) Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The mitogen activated protein kinase (MARK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *J Mol Med (Berl)*. 2012 Jun;90(6):667-79, 2012.

101) Falvo E, Strigari L, Citro G, Giordano C, Bobec G, Fabretti F, Bruzzaniti V, Bellesi L, Muti P, Blandino G, Pinnarò P. SNPs in DNA repair or Oxidative Stress Genes and Late Subcutaneous Fibrosis in Patients following a Single Shot Partial Breast Irradiation. *J ECCR*. Jan 24;31:7, 2012.

102) Blandino G*, Valerio M, Ciocce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Gennaro Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER, microRNAs and c-MYC. *Nat Commun*. May 29;3:865 (*corresponding author), 2012.

103) Cordelli E, Eleuteri P, Grollino M, Benassi B, Blandino G, Bartoleschi C, Pardini M, Di Caprio E, Spanò M, Pacchierotti F, Villani P. Direct and delayed X-ray induced DNA damage in male mouse germ cells. *Environ Mol Mutagen*. Jul;53(6):429-39, 2012.

104) Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E and Blandino G. miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumors. *EMBO Mol Med*. Nov;4(11):1214-29, 2012.

105) Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A., and Blandino G. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. *Cell Death Dis*. Nov 15;3:e423, 2012.

- 106) Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G. Hippo and rassf1a Pathways: A Growing Affair. *Mol Biol Int.* 2012;307628, 2012.
- 107) Santoro R, Marani M, Blandino G, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. *Carcinogenesis.* May;34(5):1051-61, 2013.
- 108) Strano S., Fausti F, Di Agostino S., Sudol M., and Blandino G. PML surfs into the HIPPO Tumor Suppressor Pathway. *Front Oncol.* Mar 1;3:36, 2013.
- 109) Di Agostino S, Strano S, and Blandino G. Gender, mutant p53 and PML: A growing "affaire" in tumor suppression and oncogenesis. *Cell Cycle.* 12, 1824-5 2013.
- 110) Mori F, Strano S, and Blandino G. MicroRNA 181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. *Cell Cycle* 12, 1823-4, 2013.
- 111) Biagioni F, Bossel-Moshe N, Fontemaggi G, Yarden Y, Domany E, and Blandino G. The locus of micro-RNA10b: a critical target for breast cancer insurgence and dissemination. *Cell Cycle* 12, 2371-5, 2013.
- 112) Schernhammer SV, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F, Krogh V, Abbagnato CA, Grioni S, Blandino G, Schunemann JH, Muti P. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. *Breast Cancer Res.* 15, R46, 2013.
- 113) Benassi B, Marani M, Loda M, and Blandino G. USP2a alters chemotherapeutic response by modulating redox. *Cell Death and Disease*, 4 e-812, 2013.
- 114) Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol S, Strano S, and Blandino G. ATM-kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner-mediated oncogenic senescence. *Cell Death and Diff.* 20, 1498-509, 2013.
- 115) Ganci F, Sacconi A, Bossel Ben-Moshe N, Mandocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, and Blandino G. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head & neck squamous cell carcinoma patients. *Annals of Oncology*, 24, 3082-8, 2013.
- 116) Pulito C, Sanli T, Ranam P, Muti P, Blandino G, and Strano S. Metformin: an ongoing journey across diabetes, cancer therapy and prevention. *Metabolites.* Nov 7;3(4):1051-75, 2013.
- 117) Fazi F, and Blandino G. microRNAs: non coding pleiotropic factors in development, cancer prevention and treatment. *Microna.* 2(2):81, 2013.
- 118) Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, and Blandino G. Gain of function mutant p53 downregulates miR-223 contributing to chemoresistance of tumor cells. *Oncogene.* Mar 20;33(12):1601-8, 2014.
- 119) Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Fontanini G, Crinò L, Blandino G. MicroRNA signature predicts sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. *Clin Colorectal Cancer.* Mar;13(1):37-45.e4, 2014.
- 120) Cioce M., Ganci F., Canu V., Sacconi, Mori F., Canino C., Korita E., Casini B., Alessandrini G., Cambria A., Carosi M., Blandino. R., Panebianco V., Facciolo F., Volinia S., Muti, P., Strano, S., Croce, C., Pass, H., and Blandino G.

Protumorigenic effects of miR-145 loss in Malignant Pleural Mesothelioma. *Oncogene*. Nov 13;33(46):5319-31, 2014.

121) Blandino G*, Fazi F, Donzelli S, Kedmi M, Sa-Chen A, Muti P, Strano S, and Yarden Y. Tumor Suppressor MicroRNAs: a novel non-coding alliance against cancer. *FEBS Lett*. 2014 Aug 19;588(16):2639-2652. (* corresponding author), 2014.

122) Goeman F, De Nicola F, De Meo P.D, Elmi, B, Castrignanò T, Pesole G, Strano S, Blandino G, Fanciulli M and Muti P. VDR primary targets by genome-wide transcriptional profiling. *J Steroid Biochem Mol Biol*. Apr 13;143C:348-356, 2014.

123) Canu V, Blandino G*, Lorenzon L. Research on microRNAs leads to new frontiers of clinical and translational relevance for gastric cancer management. *Translational Gastrointestinal Cancer*. Vol 3, No 2, April. (*corresponding author), 2014.

124) Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, and Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. *Mol Cell Ther*. 2014 Jun 1;2:16, 2014.

125) Dinami R, Ercolani C, Piazza S, Ciani Y, Petti E, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeffner S. miR-155 drives telomere fragility in human breast cancer by targeting TRF1. *Cancer Res*. Aug 1;74(15):4145-56, 2014.

126) Ganci F, Vico C, Korita E, Sacconi A, Gallo E, Mori F, Cambria A, Russo E, Anile M, Vitolo D, Pescarmona E, Blandino R, Facciolo F, Venuta F, Blandino G, Marino M, Fazi F. MicroRNAs Expression Profiling of Thymic Epithelial Tumors. *Lung Cancer*, Aug;85(2):197-204, 2014.

127) Santini S, Di Agostino S, Coppari E, Bizzarri A.R, Blandino G, Cannistaro S. Interaction of mutant p53 with p73: A surface plasmon resonance and atomic force spectroscopy study. *Biochim Biophys Acta*. Jun;1840(6):1958-64, 2014.

128) Cioce M, Valerio MC, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Muti P, Strano S, and Blandino G. Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. *Oncotarget*. Jun 30;5(12):4129-43, 2014.

129) Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, Ten Hacken E, Bertilaccio S, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson P, Carrasco R, Kimmelman AC, Wong K, Caligaris-Cappio F, Blandino G, Kuehl V, Anderson KC, and Tonon G. Rescue of YAP1 triggers DNA damage-induced apoptosis in hematological cancers. *Nature Medicine*, Jun;20(6):599-606, 2014.

130) Bashk S, and Blandino G. Tumor Suppression. Editorial in *FEBS Letters*, Aug 19;588(16):2557, 2014.

131) Donzelli S, Strano S, and Blandino G. MicroRNAs: short non-coding bullets of gain of function mutant p53 proteins. *Oncoscience*. 2014 Jun 7;1(6):427-33, 2014.

132) Pulito C, Donzelli S, Muti P, Puzzo L, Strano S, and Blandino G. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. *Ann Transl Med*. Jun;2(6):58, 2014.

133) Muti P, Sacconi A, Hossain A, Donzelli S, Bossel N, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G. Downregulation of microRNAs 145-3p and 145-5p is a Long-Term Predictor of Postmenopausal Breast Cancer Risk: the ORDET prospective study. *Cancer Epidemiol Biomarkers Prev*. Nov;23(11):2471-81, 2014.

- 134) Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, Muti P, Strano S, Spriano G, Fontemaggi G, and Blandino G. microRNAs expression as predictor of local recurrence risk in oral squamous cell carcinoma. *Head Neck*. 2014 Dec 22. doi: 10.1002/hed.23959.
- 135) Valenti F, Ganci F, Fontemaggi G, Strano S, Blandino G*, and Di Agostino S. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptional downregulate BRCA1 and RAD17 gene expression. *Oncotarget*. Mar 20;6(8):5547-66. (*co-corresponding author), 2015.
- 136) Mori F, Sacconi A, Canu V, Ganci F, Novello M, Anelli V, Covello R, Ferraresi V, Muti P, Biagini R, Blandino G*, and Strano S. miR-181c associated with relapse of high grade osteosarcoma. *Oncotarget*. Jun 10;6(16):13946-61. (*corresponding author), 2015.
- 137) Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. *Biochim Biophys Acta*. Jan;1853(1):89-100, 2015.
- 138) Kedmi M, Ben-Chetrit N, Kömer C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S, Blandino G, Yarden Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. *Sci Signal*. Mar 17;8(368):ra29, 2015.
- 139) Adi Harel S, Bossel Ben-Moshe N, Aylon Y, Bublik DR, Moskovits N, Toporoff G, Azaiza D, Biagioni F, Fuchs G, Wilder S, Hellman A, Blandino G, Domany E, Oren M. Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. *Cell Death Differ*. 2015 Aug;22(8):1328-40, 2015.
- 140) Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Gentileschi MP, Germoni S, Monteleone V, Pellegrino M, Kann M, De Meo PD, Pallocca M, Höpker K, Moretti F, Mattei E, Reinhardt HC, Floridi A, Passananti C, Benzinger T, Blandino G, Fanciulli M. Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. *Cell Death Dis*. May 21;6:e1764, 2015.
- 141) Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. *EMBO J*. May 5;34(9):1214-30, 2015.
- 142) O'Brien AJ, Villani LA, Broadfield LA, Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P, Steinberg GR. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. *Biochem J*. Jul 15;469(2):177-87, 2015.
- 143) Canino C, Luo Y, Marcato P, Blandino G, Pass H and Cioca M. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. *Oncotarget*. May 20;6(14):12637-53, 2015.
- 144) Pulito C, Terrenato I, Di Benedetto A, Sacconi A, Biagioni F, Blandino G, Strano S, Muti P, Mottiolese M, and Falvo E. Cdx2 VDR polymorphism affects the activities of Vitamin D Receptor in human breast cancer cell lines and human breast carcinomas. *PLoS One*. Apr 7;10(4):e0124894, 2015.
- 145) Fontemaggi G, Bellissimo T, Donzelli S, Iosue I, Benassi B, Bellotti G, Blandino G, Fazi F. Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. *RNA Biol*. 12(7):690-700, 2015.

- 146) Pulito C, Mori F, Sacconi A, Casadei L, Ferraiuolo M, Valerio MC, Santoro R, Goeman F, Maidecchi A, Mattioli L, Manetti C, Di Agostino S, Muti P, Blandino G and Strano S. Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. *Oncotarget*. Jul 20;6(20):18134-50, 2015.
- 147) Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Biciato S, Piazza S, Strano S, Del Sal G, Blandino G. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. *EMBO Rep*. 2015 Dec 21. pii: e201540488. [Epub ahead of print]
- 148) Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pomplii A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y and Blandino G. Epigenetic silencing of miR-145-5p contributes to brain metastasis. *Oncotarget*. Nov 3;6(34):35183-201, 2015.
- 149) Bellissimo T, Russo E, Ganci F, Vico C, Vitolo D, Anile M, Disio D, Blandino G, Venuta F, and Fazi F. Circulating miR-21-5p and 148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. *Cancer Biol Ther*. 2015 Nov 17:0. [Epub ahead of print]
- 150) Strano S, Muti P and Blandino G. What biomarkers (if any) for precise medicine? *Aging (Albany NY)*. Aug;7(8):533-4, 2015.
- 151) Frixa T, Donzelli S, and Blandino G. Oncogenic microRNAs: key players in malignant transformation. *Cancers (Basel)*. Dec 18;7(4):2466-85, 2015.
- 152) Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Ferrandina G, Sacconi A, Blandino G, Bagnato A. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. *Oncotarget*. 2015 Dec 10. doi: 10.18632/oncotarget.6546. [Epub ahead of print]
- 153) Donzelli S, Ciocce M, Muti P, Strano S, Yarden Y and Blandino G. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signaling in cancer. *Semin Cell Dev Biol*. 2016 Feb;50:133-42.
- 154) Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, Blandino G* and Strano S. Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. *Oncotarget*. 2016 Apr 12;7(15):20532-48.
- 155) Ferraiuolo M, Di Agostino S, Blandino G and Strano S. Oncogenic Intra-p53 family interactions in human cancers. *Front Oncol*. 2016 Mar 31;6:77.
- 156) Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Di Agostino S, Blandino G, Avantaggiati ML and Chung FL. Reactivation of mutant p53 by a dietary-related compound, phenethyl isothiocyanate inhibits tumor growth. *Cell Death Differ*. 2016 Oct;23(10):1615-27.
- 157) Cordani M, Oppici E, Dando I, Butturini E, Pozza E, Nadal-Serrano M, Oliver J, Roca P, Marioitto S, Cellini B, Blandino G, Palmieri M, Di Agostino S, Donadelli M. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. *Mol Oncol*. 2016 Aug;10(7):1008-29.
- 158) Ciocce M., Strano S., Muti P, Blandino G. Mir 145/143: tumor suppressor, oncogenic microenvironmental factor ... or both? *Aging (Albany NY)*. 2016 May;8(5):1153-5.
- 159) Catena V., Bruno T., De Nicola F., Goeman F., Pallocca M., Iezzo S., Sorino C., Cigliana G., Floridi A., Blandino G., and Fanciulli M. Depror transcriptionally

regulates Endoplasmic Reticulum homeostasis in Multiple Myeloma cells. *Oncotarget*. 2016 Oct 25;7(43):70546-70558.

160) Pass H., Lavilla C., Canino C., Goparaja C., Noreen S., Blandino G., and Cioce M. Inhibition of the Colony-Stimulating-Factor 1 Receptor affects the resistance of lung cancer cells to cisplatin. *Oncotarget*. 2016 Aug 30;7(35):56408-56421.

161) Gentileschi MP, Lattanzi C., Menicagli F., Vincenzi B., Cigliana G., Baldi A., Blandino G., Muti P., Fanciulli M., Spugnini E. Dietary protective effects against hepatocellular carcinoma development in Mdr2-/- knock-out mice. *In Vivo*. 2016 Jul-Aug;30(4):445-50.

162) Editorial: Haupt Y., and Blandino G. Human tumor-derived p53 mutants: a growing family of oncoproteins. *Front Oncol*. 2016 Jul 12;6:170.

163) Mao Y., Chen X., Fujita K., Motoki K., Sasabe T., Homma H., Tagawa K., Tamura T., Kaye J., Finkbeiner S., Blandino G., Sudol S., and Okazawa H. Targeting TEAD/YAP-transcription-dependent necrosis TRIAD, ameliorates Huntington's disease pathology. *Hum Mol Genet*. 2016 Sep 12. pii: ddw303. [Epub ahead of print]

164) Lo Sardo F, Forcato M, Capaci V., Sacconi A, Di Agostino S, Zancanato F, Del Sal G., Strano S, Bicciato S, and Blandino G. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

165) Milella M., Falcone I., Conciatori F., Matteoni S., Sacconi A., De Luca T., Bazzichetto C., Corbo V., Simbolo M., Sperduti I., Benfanti A., Del Curatolo A., Cesta Incani U., Malusa F., Eramo A., Sette G., Scarpa A., Konopleva M., Andreeff M., McJubrey J., Blandino G., Todaro M., Stassi G., De Maria R., Cognetti F., Del Bufalo D., and Ciuffreda L. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. *Sci Rep*. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

166) Bruno T, Valerio MC, Casadei L, De Nicola F, Goeman F, Pallocca M, Cafena V, Iezzi S, Sorino C, De Santis A, Manetti C, Blandino G, Floridi A, and Fanciulli M. Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1 stabilization. *J Exp Clin Cancer Res*. 2017 Feb 18;36(1):32. doi: 10.1186/s13046-017-0497-1.

167) Canu V., Sacconi A., Lorenzon L., Biagioni F., Lo Sardo F., Muti P., Garofalo A., Strano S., D'Emico A., Grazi GL, Cioce M., and Blandino G. MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. *Oncotarget*. 2017 May 2;8(18):29540-29557. doi: 10.18632/oncotarget.15290.

168) Raghu D., Paul P., Gulati T., Deb S., Khoo C., Russo A., Gallo E., Blandino G., Chan AL., Takano E., Fox S., Williams S., Haupt S., Gamell C., Haupt Y. EA6P promotes prostate cancer by reducing p27 expression. *Oncotarget*. 2017 Jun 27;8(26):42939-42948. doi: 10.18632/oncotarget.17224.

169) Lorenzon L., Cipitelli C., Avantifiori R., Uccini S., French D., Torrisi MR., Ranieri D., Mercantini P., Canu V., Blandino G., and Cavallini M. Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. *J Surg Oncol*. 2017 Aug;116(2):184-194. doi: 10.1002/jso.24648. Epub 2017 May 5.

170) Houde V., Donzelli S., Sacconi A., Galic S., Hammill JA., Bramson JL., Foster RA., Tsakiridis T., Kemp B., Grasso G., Blandino G., Muti P., and Steinberg G. Genetic loss of AMPK B1 accelerates tumorigenesis in vivo. *Mol Oncol*. 2017 Sep;11(9):1143-1155. doi: 10.1002/1878-0261.12079. Epub 2017 Jun 28.

- 171) Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Diso D, Anile M, Petrozza V, Giangaspero F, Pescarmona E, Facciolo F, Venuta F, Marino M, Blandino G*, and Fazi F. Thymic epithelial tumors phenotype relies on miR-145-5p epigenetic regulation (*co-corresponding author). *Mol Cancer*. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.
- 172) Goeman F, Strano S, and Blandino G. MicroRNAs as key effectors in the p53 network. *Int Rev Cell Mol Biol*. 2017;333:51-90. doi: 10.1016/bs.icmb.2017.04.003. Epub 2017 May 22.
- 173) Ferraiuolo M, Verduci L, Blandino G, and Strano S. Mutant p53 and the Hippo transducers YAP and TAZ: a critical oncogenic node in human cancers. *Int J Mol Sci*. 2017 May 3;18(5). pii: E961. doi: 10.3390/ijms18050961. Review.
- 174) Ganci F, Sacconi A, Manciooco V, Covello R, Benevolo M, Rollo F, Spriano G, Strano S, Valsoni S, Biciato S, Muti P, Fontemaggi G, and Blandino G. Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. *Mod Pathol*. 2017 Oct;30(10):1387-1401. doi: 10.1038/modpathol.2017.62. Epub 2017 Jul 21.
- 175) Prusko M, Milano E, Forcalo M, Donzelli S, Ganci F, Di Agostino S, Bates D, Biciato S, Zyllic M, Zyllic A, Blandino G*, Fontemaggi G. The mutant p53-ID4 complex controls VEGFA isoforms production by recruiting lncRNA MALAT1. (*co-corresponding author *EMBO Rep*. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26.
- 176) Rizzo A, Donzelli S, Grgenti V, Sacconi A, Vasco C, Salmaggi A, Blandino G, Maschio M, Ciusani E. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. *J Exp Clin Cancer Res*. 2017 Jun 6;36(1):76. doi: 10.1186/s13046-017-0546-9.
- 177) Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, Campagnoli C, Berrino F, Fanciulli M, Ford RJ, Ciuffreda L, Milella M, Steinberg G, Cioce M, Muti P, Strano S, and Blandino G. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L anti-tumoral activities. *Cell Discov*. 2017 Jul 4;3:17022. doi: 10.1038/celldisc.2017.22. eCollection 2017.
- 178) Masciarelli S, Capuano E, Ottone T, Divona MD, De Panfilis S, Banella C, Noguera N, Picardi A, Fontemaggi G, Blandino G, Lo Coco F, and Fazi F. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER-stress. *Leukemia*. 2017 Aug 4. doi: 10.1038/leu.2017.231. [Epub ahead of print]
- 179) Dinami R, Sestito R, Buemi V, Zappone A, Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, Piazza S, Benetti R, Schoeftner S. Silencing of miR296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. *Oncotarget*. 2017 Sep 23;8(56):95674-95691. doi: 10.18632/oncotarget.21180. eCollection 2017 Nov 10.
- 180) Muti P, Donzelli S, Sacconi A, Hossain A, Frixia T, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene Y, Yarden Y, Blandino G. miRNA 513a-5p is an age-independent long-term predictor on breast cancer in premenopausal women. *Carcinogenesis*. 2017 Nov 4. doi: 10.1093/carcin/bgx126. [Epub ahead of print]
- 181) Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Colombo T, Paci P, Strano S, Macino G, Rajesky N, and Blandino G. The oncogenic role of Circ-6 in Head and Neck Squamous Cell Carcinoma is mediated through mutantp53/YAP/TEAD complex. *Genome Biol*. 2017 Dec 20;18(1):237. doi: 10.1186/s13059-017-1368-y.

- 182) Lo Sardo F., Muti P., Blandino G and Strano S. Metatonin and Hippo pathway: is there existing cross-talk? *Int J Mol Sci.* 2017 Sep 6;18(9). pii: E1913. doi: 10.3390/ijms18091913.
- 183) Frixia T., Sacconi A., Cioce M., Roscilli G., Ferrara Fosca F., Aurisicchio L., Pulito C., Telera S., Carosi MA., Strano S., Donzelli S., and Blandino G. MicroRNA-128-mediated depletion of Drosha promotes lung cancer cell migration. *Carcinogenesis.* 2017 Dec 11. doi: 10.1093/carcin/bgx134. [Epub ahead of print]
- 184) Di Martino S., Amoreo CA., Nuvoli B., Galati R., Strano S., Facciolo F., Pass H., Ciliberto G., Blandino G., De Maria R., Cioce M. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. *Oncogene.* 2018 Jan 9. doi: 10.1038/s41388-017-0044-8. [Epub ahead of print].
- 185) Folgiero V., Sorino C., Pallocca M., De Nicola F., Goeman F., Bertaina V., Strocchio L., Romania P., Pitisci A., Iezzi S., Catena V., Bruno T., Strimpakos G., Passananti C., Maitel E., Blandino G., Locatelli F., and Fanciulli M. Che-1 is a new c-Myc target that sustains proliferation in pre-B-cell acute lymphoblastic leukemia. *EMBO Rep.* 2018 Jan 24. pii: e44871. doi: 10.15252/embr.201744871. [Epub ahead of print]
- 186) Di Modugno F., Caprara V., Chielli L., Tocci P., Spadaro F., Ferrandina G., Sacconi A., Blandino G., Nisticò P., Bagnato A., and Rosanò L. hMENA is a key regulator in endothelin-1/ β -arrestin1-induced invadopodial function and metastatic process. *Proc Natl Acad Sci U S A.* 2018 Mar 20;115(12):3132-3137. doi: 10.1073/pnas.1715998115. Epub 2018 Feb 8.
- 187) Di Agostino S., Valenti F., Sacconi A., Fontemaggi G., Pallocca M., Ganci F., Muti P., Strano S., and Blandino G. Aberrant activation of MIR205HG gene by mutant p53 protein elicits unrestrained proliferation in Head and Neck squamous cell carcinoma. *Theranostics.* 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.
- 188) Radovich M., et al. (Blandino G., in The Cancer Genome Atlas Research Network). The integrated genomic landscape of thymic epithelial tumors. *Cancer Cell.* 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.
- 189) Tang GH, Saktunan M., Pond GR, Steinberg GR, Blandino G., Schunemann H., Muti P. Association of metformin with breast cancer incidence and mortality in patients with type 2 diabetes: a GRADE 2 assessed systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2018 Apr 4. pii: cebp.0936.2017. doi: 10.1158/1055-9965.EPI-17-0936. [Epub ahead of print]
- 190) Donzelli S., Milano E., Iosue I., Melucci E., Gallo E., Prusko M., Zylic A., Zylic M., Terrenato I., Mottolose M., Fazi F., Blandino G* and Fontemaggi G. Expression of ID4 protein in breast cancer cells determines reprogramming of tumor-associated macrophages. (*co-corresponding author). *Breast Cancer Res.* 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.
- 191) Blandino G. and Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. *J Exp Clin Cancer Res.* 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7. Review.
- 192) Marchesi F., Regazzo G., Palombi F., Terrenato I., Sacconi A., Spagnuolo M., Donzelli S., Marino M., Ercolani C., Di Benedetto A., Blandino G., Ciliberto G., Mengarelli A., Rizzo MG. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. *J Exp Clin Cancer Res.* 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5.

- 193) Prusko M., Milano E., Zylic A., Zylic M., Blandino G., Fontemaggi G. Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo. *J Thorac Dis* 2018;10(3):E231-E233
- 194) Lo Sardo F., Strano S., and Blandino G. YAP and TAZ in lung cancer: oncogenic role and clinical targeting. *Cancers (Basel)*. 2018 May 6;10(5). pii: E137. doi: 10.3390/cancers10050137. Review.
- 195) Ferraiuolo M., Pulito C., Finch-Edmonson M., Korita E., Maidecchi A., Donzelli S., Muti P., Serra M., Sudol M., Strano S., Blandino G. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. *Cancer Letters*, 2018, Jun 19;433:18-32. doi: 10.1016/j.canlet.2018.06.021. [Epub ahead of print]
- 196) Spagnuolo M., Regazzo G., Dedominici M., Sacconi A., Pelosi A., Picari E., Lo Spinoso Severini F., Marchesi F., Magenta A., Masi S., Cordone I., Mengarelli A., Strano S., Blandino G., Rizzo MG., Calabretta B. Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. *Haematologica*. 2019 Jan;104(1):82-92. doi: 10.3324/haematol.2018.191213. Epub 2018 Aug 3.
- 197) Belloni L., Di Cocco S., Gurneri F., Nunn ADG., Piconese S., Salerno D., Testoni B., Pulito C., Mori F., Pallocca M., Sacconi A., Vivoli S., Marra F., Strano S., Blandino G., Leviero M., Pediconi N. Targeting a phospho-STAT3-miRNAs pathway improves vesicular steatosis in an in vitro and in vivo model. *Sci Rep*. 2018 Sep 11;8(1):13638. doi: 10.1038/s41598-018-31835-2.
- 198) Blandino G., Lo Sardo F. In vivo experimental models account for higher complexity than in vitro preclinical setting in cancer. *Journal of thoracic disease* vol. 11, Suppl 3 (2019): S461-S464. doi:10.21037/jtd.2018.11.17
- 199) Bellissimo T., Tito C., Ganci F., Sacconi A., Masciarelli S., Di Martino G., Porta N., Cirenza M., Sorci M., De Angelis L., Rosa P., Calogero A., Fatiga A., Petrozza V., Fontemaggi G., Blandino G., Fazi F. Argonaute 2 drives miR-145-5p gene expression program in breast cancer cells. *Cell Death Dis*. 2019 Jan 8;10(1):17. doi: 10.1038/s41419-018-1267-5.
- 200) Verduci L., Strano S., Yarden Y., and Blandino G. The circRNAs-microRNA code: emerging implications for cancer diagnosis and treatment. *Mol Oncol*. 2019 Feb 4. doi: 10.1002/1878-0261.12468. [Epub ahead of print] Review.
- 201) Zizza P., Dinami R., Porru E., Cingolani C., Salvati E., Rizzo A., D'Angelo C., Petti E., Amoreo CA., Mottola M., Sperduti I., Chambery A., Russo R., Ostano P., Chiorino G., Blandino G., Sacconi A., Cherfils-Vicini J., Leonetti C., Gilson E., Biroccio A. TRF2 positively regulates SULF2 expression VEGF-A release and activity in tumor microenvironment. *Nucleic Acids Res*. 2019 Jan 30. doi: 10.1093/nar/gkz041. [Epub ahead of print]
- 202) Vahabi M., Pulito C., Sacconi A., Donzelli S., D'Andrea M., Manciooco V., Pellini R., Paci P., Sanguineti G., Strigari L., Spriano G., Muti P., Pandolfi PP., Strano S., Safarian S., Ganci F., and Blandino G. miRNA-95-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. *J Exp Clin Cancer Res*. 2019;38(1):141. Published 2019 Mar 29. doi:10.1186/s13046-019-1119-x
- 203) Strano S., Donzelli S., Blandino G. Long non-coding RNA MALAT1 as metastasis suppressor. *Precision Cancer Medicine*, doi: 10.21037/pcm.2019.02.02
- 204) Verduci L., Blandino G. Circulat RNA YAP1: a new player in gastric cancer. *Translational Cancer Research*, doi: 10.21037/tcr.2019.02.04
- 205) Strano S., Blandino G. cTAZ: a safeguard factor of antiviral response. *EMBO Rep*. 2019 Apr 17. pii: e48169. doi: 10.15252/embr.201948169.

- 206) Blandino G, Valentini F, Sacconi A, Di Agostino S. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. *Seminars in Cell and Developmental Biology*. 2020 in press.
- 207) Tocci P, Cianfrocca R, Di Castro V, Rosano L, Sacconi A, Donzelli S, Bonfiglio S, Bucci G, Vizza E, Ferrandina G, Scambia G, Tonon G, Blandino G*, Bagnato Anna. B-Arrestin1/YAP/mutant p53 complexes orchestrate the endothelin receptor A signaling in highgrade serous ovarian cancer. (*co-corresponding author). *Nat Commun*. 2019;10(1):3196. Published 2019 Jul 19. doi:10.1038/s41467-019-11045-8
- 208) Di Agostino S, Fontemaggi G, Strano S, Blandino G, D'Orazi G. Targeting mutant p53 in cancer: the latest insights. *J Exp Clin Cancer Res*. 2019;38(1):290. Published 2019 Jul 5. doi:10.1186/s13046-019-1302-0
- 209) Pulito C, Korita E, Sacconi A, Valerio MC, Casadei L, Io Sardo F, Mori F, Ferraiuolo M, Grasso G, Maidecchi A, Lucci J, Sudol M, Muti P, Blandino G*, Strano S. Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. *J Exp Clin Cancer Res*. 2019;38(1):349. Published 2019 Aug 9. doi:10.1186/s13046-019-1352-3. * Co-corresponding author.
- 210) Valentini F, Sacconi A, Ganci F, Grasso G, Strano S, Blandino G*, Di Agostino S. (* co-corresponding author). The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. *Cancers (Basel)*. 2019;11(9):1347. Published 2019 Sep 11. doi:10.3390/cancers11091347
- 211) Gamell C, Bandilovska I, Guleti T, Kogan A, Lim SC, Kovacevic Z, Takano EA, Timpone C, Agupitan AD, Litchfield C, Blandino G, Horvath LG, Fox SB, Williams SG, Russo A, Gallo E, Paul PJ, Mitchell C, Sandhu S, Keam SP, Haupt S, Richardson DR, Haupt Y. EGAP promotes a metastatic phenotype in prostate cancer. *iScience*. 2019;22:1–15. doi:10.1016/j.isci.2019.10.065
- 212) Ganci F, Pulito C, Valsoni S, Sacconi A, Turco C, Vehabi M, Manciooco V, Mazza E, Meens J, Karamboulas C, Nichols A, Pellini R, Spriano G, Sanguineti G, Muti P, Biciato S, Ailles L, Strano S, Fontemaggi G, Blandino G. PI3K inhibitors curtail Myc-dependent mutant p53 gain of function in head and neck squamous cell carcinoma. *Clin Cancer Res*. 2020 Jan 22. pii: clincanres.2485.2019. doi: 10.1158/1078-0432.CCR-19-2485. [Epub ahead of print]
- 213) Donzelli S, Sacconi A, Turco C, Gallo E, Iosue I, Blandino G*, Fazi F, Fontemaggi G. Paracrine signaling from breast cancer cells causes activation of ID4 expression in tumor-associated macrophages. *Cells*. 2020 Feb 11;9(2). pii: E418. doi: 10.3390/cells9020418. (*co-corresponding author).
- 214) Tupone MG, D'Aguanno S, Di Martile M, Valentini E, Desideri M, Triscioglio D, Donzelli S, Sacconi A, Buglioni S, Ercolani C, Biagioni A, Fibbi G, Faltore L, Mancini R, Ciliberto G, Blandino G, Del Bufalo D. microRNA-378-5p is a novel positive regulator of melanoma progression. *Oncogenesis*. 2020 Feb 14;9(2):22. doi: 10.1038/s41389-020-0203-6.
- 215) de Feo M, De Leo C, Romeo U, Muti P, Blandino G, Di Agostino S. Arenavirus as a potential etiological agent of odontogenic tumors in humans. *J Exp Clin Cancer Res* 2020 Feb 10;39(1):34. doi: 10.1186/s13046-020-1540-1.
- 216) Canese R, Bazzocchi A, Blandino G, Carpinelli G, De Nuccio C, Gion M, Moretti F, Soricelli A, Spessotto P, Iorio E. The role of molecular and imaging biomarkers in the evaluation of inflammation in oncology. *Int. Jour. Of Biomark.* . 2020 Feb;35(1_suppl):5-7. Doi: 10.1177/1724600819897926.

- 217) Pulito C., Strano S., Blandino G. Dihydroartemisin : from malaria to the treatment of relapsing head and neck cancers. *Annals Translational Medicine*, in press, 2020.
- 218) Donzelli S., Farneti A., Marucci L., Ganci F., Sacconi A., Strano S., Sanguineti G., Blandino G. Non-coding RNAs as putative biomarkers of cachexia in head and neck cancer patients. *Front Cell Dev Biol*. 2020 Apr 21;8:257. doi: 10.3389/fcell.2020.00257. eCollection 2020.
- 219) Blandino G. Cancer at the time of the COVID-19 hurricane. *J Exp Clin Cancer Res*. 2020 Apr 29;39(1):74. doi: 10.1186/s13046-020-01575-1.
- 220) Dinami R., Porru M., Amoreo CA., Sperduti I., Mottolise M., Buglioni S., Marinelli D., Maugeri-Sacca M., Sacconi A., Blandino G., Leonetti C., Di Rocco G., Verdina A., Spinella F., Fiorentino F., Ciliberto G., Biroccio A., Zizza P. TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. *Journal of Experimental & Clinical Cancer Research*, 2020 in press.
- 221) Shreberk-Shaked M., Dassa B., Sinha S., Di Agostino S., Azuri I., Mukherjee S., Aylon Y., Blandino G., Ruppin E., and Oren M. Division of labor between YAP and TAZ in non-small lung cancer. Under second revision in *Cancer Research*, 2020.
- 222) Sestito R., Cianfrocca R., Tocci P., Rosanò L., Sacconi A., Blandino G., and Bagnato A. Interdependent regulation of ETAR miR200b/c-Zeb1 circuit promotes ovarian cancer progression. Under second revision in *Communication Biology*, 2020.
- 223) Canu V., Donzelli S., Sacconi A., Pulito C., Bossel N., Di Benedetto A., Muti P., Botti C., Domany E., Biocciato S., Strano S., Yarden Y., Blandino G. Aberrant transcriptional and posttranscriptional regulation of SPAG5, A Hippo pathway component, fuels breast cancer cell proliferation. Under second revision in *Cell Death and Differentiation*, 2020.
- 224) Di Agostino S., Riccioli A., De Cesaris P., Fontemaggi G., Blandino G., Filippini A., Fazi F. Circular RNAs in embryogenesis and cell differentiation with a special focus on cancer development. *Frontiers in Cell Development and Biology*, in press, 2020.
- 225) Tocci P., Cianfrocca R., Sestito R., Rosanò L., Di Castro V., Blandino G., Bagnato A. Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Submitted to *Cancer Letters*, 2020.
- 226) D'Amore A., Hanbashi A., Di Agostino S., Palombi F., Sacconi A., Voruganti A., Taggi M., Canipari R., Blandino G., Parrington J., Filippini A. Loss of pre-two channel (TPC2) expression increases the metastatic potential of melanoma cells by a mechanism involving the Hippo signalling pathway and store-operated calcium entry. Submitted to *Cancer Research*, 2020.
- 227) Tito C., Ganci F., Sacconi A., Masciarelli S., Fontemaggi G., Pulito C., Gallo E., Laquintana V., Ialza A., De Angelis L., Cacciotti J., Carè A., Fatica A., Diso D., Anile M., Petrozza V., Facciolo F., Alessandrini G., Pescarmona E., Venuta F., Marino M., Blandino G.*, Fazi F. (*co-corresponding author). LINC00174 is a novel prognostic factor in Thymic Epithelial Tumors involved in cell migration and lipid metabolism. Submitted to *Cell Death and Disease*, 2020.
- 228) Lo Sardo F., Pulito C., Sacconi A., Korita E., Sudol M., Strano S., and Blandino G. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small lung cancer. Submitted to *Genome Biology*, 2020.

LIBRI E CAPITOLI DI LIBRI

- 229) Sacconi A., Donzelli S., Pulito C., Ferrero S., Morrone A., Rigoni M., Pimpinelli F., Ensoli F., Sanguineti G., Pellini R., Agrawal N., Izumchenko E., Ciliberto G., Gianni A., Muli P., Strano S. and Blandino G. TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Deposited to BioRxiv, 2020 <https://doi.org/10.1101/2020.06.16.154211>.
- 1) Rizzo M.G, Soddu S, Crescenzi M, Blandino G, Scardigli R, Coen S, Sacchi A. Wild-type p53 overexpression diversely affects different leukemia cells. Proceedings of the XVI International Cancer Congress 1994. New Delhi (India), October 30-November 5. Monduzzi Editore, 1994.
- 2) Monti O, Damalas A, Strano S, and Blandino G. p73, p63 and mutant p53: members of protein complexes floating in cancer cells. Book for "25years of p53 research" by Kluwer Academic Publishers, 2005.
- 3) Blandino G. Gain of function p53. Encyclopedia of Cancer, 2nd edition by Springer Publisher, 2008.
- 4) Ganci F, Sacconi A, Manciocco V, Spriano G, Fontemaggi G, Blandino G. Molecular genetics and biology of head and neck squamous cell carcinoma: implications for diagnosis, prognosis and treatment. Head and Neck Cancer (ISBN 979-953-307-914-0), 2012.
- 5) Blandino G and Fontemaggi G. Id4 (Inhibitor of DNA binding). Encyclopedia of Signaling Molecules. Springer, 2012.
- 6) Goeman F, Fontemaggi G, Blandino G. ChIP-on-chip to identify mutant p53 targets. p53 Protocols: Second edition. Humana Press. Springer, 2012.
- 7) Donzelli S, Strano S, Blandino G. Yap and p73: a matter of mutual specificity in tumor suppression. The Hippo Signaling pathway and cancer. Springer, 2013.
- 8) Santoro R, Ferraiuolo M, Blandino G, Muli P, and Strano S. Melatonin Receptors and their Preventive Role in Carcinogenesis. Melatonin: Therapeutic Value and Neuroprotection. CRC Press. Chapter 18. Pages 223–232, 2014.
- 9) Santoro R, Strano S, Blandino G. Transcriptional Regulation by Mutant p53 and Oncogenesis. Mutant p53 and MDM2 in Cancer. Springer. Volume 85 of the series Subcellular Biochemistry pp 91-103, 2014.
- 10) Ganci F, Sacconi A, Manciocco V, Spriano G, Fontemaggi G, Carlini P and Blandino G. Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. Intech. Chapter 1. ISBN 978-953-51-2135-0, July 8, 2015.
- 11) Mori F, Canu V, Lorenzon L, Garofalo A, Blandino G, Strano S. Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. Methods Mol Biol. 1379:129-37, 2016.
- 12) Ganci F, Blandino G. microRNAs in Cancer Chemoprevention: Method to Isolate Them from Fresh Tissues. Methods Mol Biol. 1379:21-9, 2016.

13) Donzelli S, Blandino G, Muli P. Use of Buffy Coat miRNA Profiling for Breast Cancer Prediction in Healthy Women. *Methods Mol Biol.* 1379:13-9, 2016.

14) Ferraiuolo M, Strano S and Blandino G. Growth factors mediated cell signalling in Hippo pathway. *Encyclopedia of Cell Biology*, Volume 3, Pages 99-106, 2016.

LETTERE (PEER-REVIEWED)

1) Muli P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Blandino G. Metformin, diet and breast cancer: An avenue for chemoprevention, *Cell Cycle*. 8:16, 1-1; 15 August, 2009.

PRESENTAZIONI NAZIONALI ED
INTERNAZIONALI SU INVITO
(SELEZIONE)

1. Speaker: The Mtp53 Consortium Kick-Off Meeting, Lillehammer, Norway, 2004.
2. Speaker: First IEO-IFOM Cancer Meeting, Milan, Italy 2004.
3. Speaker: 26th Meeting of the European Study Group for Cell Proliferation (ESGCP), Prague, Czechoslovakia 2004.
4. Speaker: OECl 25th Annual Meeting, Berlin, Germany 2004.
5. Speaker: The Active p53 Consortium Kick-Off Meeting, Ghent, Belgium 2004.
6. Speaker: Life Sciences FP6 European Research Proposals Meeting, Poland 2005.
7. Speaker: P53 Marathon, Ein Gedi, Israel, 2005.
8. Speaker: 2nd IFOM –IEO Cancer Meeting, Milan, Italy 2006.
9. Speaker: International p53 Workshop, New York, USA 2006.
10. Speaker: P53 Marathon, Frascati, Italy 2006.
11. Speaker: XIV Telethon Scientific Convention, Salsomaggiore, Italy 2007.
12. Speaker: 3rd International p73/p63 Workshop, Rome, Italy 2007.
13. Speaker: World Stress Conference, August 25th. Title: "p53 family in apoptosis". Budapest, Hungary 2007.
14. Speaker: FEBS Workshop: The Biology of Modular Protein Domains, September 11th. Title: "The WW domain of YAP is critical in the execution of p73-mediated apoptosis in response to DNA damage". Seefeld, Austria 2007.
15. Speaker: Cancer Therapeutics: The Road Ahead, October 8th. Title: "Mutant p53 Gain of Function: SIMPs-mediated Disruption of the Protein Complex mtp53/p73 Enhances Selectively the Chemosensitivity of Mutant p53 Tumor Cells". Capri, Italy 2007.
16. Speaker: P53 Marathon. Deregulating the p53 Network: Origin and Consequences of TP53 mutations, November 14th. Title: "Mutant p53: an oncogenic transcription factor". Lyon, France 2007.
17. Speaker: Era of Hope Department of Defense Breast Cancer Research Program Meeting, June, Baltimore, USA 2008.
18. Speaker. Title: "The Potential of Metformin Use in Breast Cancer", Turin, Italy, 2009.
19. Speaker: P53 Marathon, March 27th. Title: "Mutant p53 triggers an oncogenic autoregulatory feedback loop". Acre, Israel 2009.

20. Speaker: University of Oxford, November 16th. Title: "Oncogenic cross-talks in human cancers". Oxford, England, 2009.
21. Speaker: 3rd International p63/73 Workshop, March 21st. Title: "Reactivation of p73 is dangerous for tumour cells". Rome, Italy, 2009.
22. Chair & Speaker: The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, April 22nd. Title: "YAP bridges p73 and PML pro-apoptotic pathways". Rome, Italy, 2009.
23. Chair & Speaker: The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, November 3rd. Title: "Role of YAP in apoptosis and senescence as tumour suppression mechanisms". Rome, Italy, 2010.
24. Speaker: Karolinska Institutet. Title: "Oncogenic cross-talks in human cancers". Stockholm, Sweden, 2010.
25. Speaker: SIBBM seminar: Frontiers in Molecular Biology, University of Padua, June 4th. Title: "Molecular determinants in breast cancer". Padova, Italy, 2010.
26. Speaker: University of Trieste, School of Molecular Biomedicine, March 30th. Title: "Exploring tumour chemoresistance: miRNAs and cancer stem cells". Trieste, Italy, 2011.
27. Speaker: Institute SanRaffaele in Milan, Department of Experimental Oncology.
28. Title: "Exploring tumor chemoresistance: miRNAs and cancer stem cells". Milano, Italy, 2011.
29. Speaker: 5th Mutant p53 Workshop: "From bench to bedside across mouse models, May 23rd. Title: "Oncogenic transcriptional activity of mutant p53". Rome, Italy, 2011.
30. Chair: Mutant p53 activities in vivo: 5th Mutant p53 Workshop: "From bench to bedside across mouse models", 24th May. Rome, Italy, 2011.
31. Speaker: 53rd Annual Meeting of the Italian Cancer Society: "Back to the future", Translating cancer research from bedside to bench and back, October 22nd. Title: "The Hippo-YAP pathway in organ size control tumorigenesis". Torino, Italy, 2011.
32. Translational Round Table, McMaster University, June 15. Title: "miRNA profiling: a way to dissect cancer alterations". Hamilton, Canada, 2012.
33. Departmental Seminar at McMaster University, June 19. Title: "Mutant p53 proteins: between loss and gain of function". Hamilton, Canada, 2012.
34. Special Guest seminar at Juravinsky Cancer Center, June 28, Title: "p53 mutations and miRNAs: a growing affair". Hamilton Canada, 2012.
35. Keynote Speaker: Retreat Meeting of the Biochemistry Department of the University of Alberta, May. Title: "Mutant p53 proteins: Between Loss and Gain of Function". Edmonton, Canada, 2013.

36. Chair: Hippo network in organ size control. The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer (E2-2013), May 19-23. Monterey, California, USA, 2013.
37. Speaker: The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer (E2-2013), May 19-23rd. Title: 'Crosstalk between p53 Family and YAP in DNA damage and Senescence'. Monterey, California, USA, 2013.
38. Chair: 6th International Mutant p53 workshop. June, 15-18. Toronto, Canada, 2013.
39. Speaker: 6th International Mutant p53 workshop. June, 15-18. Title: "Mutant p53 and miRNAs: a growing affaire in tumorigenesis". Toronto, Canada, 2013.
40. Special Guest Seminar at the Weizmann Institute of Science, December 12. Title: "miRNAs: non-coding pleiotropic factors in cancer". Rehovot, Israel, 2013.
41. Invited Speaker at the Cancer Colloquium Univ. of St. Andrews, February 18-21. Title: "The protein complex YAP/PML in apoptosis and senescence". St. Andrews, Scotland, UK, 2014.
42. Invited Speaker at the 16th p53 Workshop Karolinska Institutet, June 15-19. Title: "The p53 and the Hippo Tumor Suppressor pathways: a growing cross-talk". Stockholm, Sweden, 2014.
43. Invited Speakers at Workshop "HIPPO in Cancer" April 15. Title: The YAP/PML protein complex cross-talks with p53 family members in apoptosis and senescence". Roma, Italy, 2014.
44. Invited Speaker at the University of Trieste, School of Molecular Biomedicine, April 4. Title: "Loss of tumor suppressor miRNAs activities in human cancers". Trieste, Italy, 2014.
45. Invited Speaker at the McMaster University Department of Medicine, February 5. Title: "microRNAs: Pleiotropic Small non-coding factor in cancer therapy". Hamilton, Canada, 2015.
46. Invited Speaker at the EPIGEN Meeting, April 24. Title: Study of mutant p53-dependent epigenetic modifications in head and neck tumors. Roma, Italy, 2015.
47. Invited Speaker at Bayer Workshop in Berlin, September 5. Title: Mutant p53 and YAP: an oncogenic transcriptional network in human cancers. Berlin, Germany, 2015.
48. Invited Speaker at the Department of Chemistry and Biochemistry, University of Windsor, Canada. Title: MicroRNAs: pleiotropic small non-coding factors in cancer therapy" April, 18, 2016.
49. Invited Speaker at the 4th Annual Emphasis Symposium on "Cancer and Metabolism: Mechanisms and Outcomes" McMaster Univ, Canada. Title: MicroRNAs: short non-coding mediators of metformin anticancer effects. April 21, 2016.

50. Invited Speaker at the 7th International Mutant p53 Workshop, Melbourne, Australia. Title: Mutant p53 surfs into non-coding RNA networks. October 26-28, 2016.
51. Invited Speaker at the 29th AICC workshop on "Mutant p53 surfs into Non-Coding RNAs Network" L'Aquila, November 23-25, 2016.
52. Invited Speaker at the SIMEeP Winter School on "Liquid Biopsy- Circulating Cell Free DNA" Rome, November 30, 2016
53. Invited Speaker at IBPM-CNR "From basic research to technology transfer". Title: Mutant p53 protein: an oncogene regulator of coding and non-coding RNA network in human cancers". Rome, May 3, 2017.
54. Invited Speaker at the Weizmann Institute of Science "Mini-symposium on Cancer and Genome" Title: Mutant p53 protein: an oncogene regulator of coding and non-coding RNA network in human cancers". Rehovot, May 15, 2017.
55. Invited Speaker at the Weizmann Institute of Science "From Statistical Mechanical to Cancer Genomics". Title: Tumor suppressor microRNAs in human breast cancer. Rehovot, May 17, 2017.
56. Invited Speaker at A* STAR Institute. Title: YAP and TAZ are critical transducers of gain of function mutant p53 proteins in human cancers. Singapore, July 7, 2017.
57. Invited Speaker at 17th p53 Workshop. Title: Aberrant crosstalk between the HIPPO and tumor suppressor pathways elicits unrestrained cell proliferation. Singapore, July 10, 2017.
58. Invited Seminar at the Weizmann Institute: Title: Non-coding RNAs are major oncogenic targets of altered tumor suppressor pathways in HNSCC tumors" Rehovot, March 15, 2018.
59. Invited Speaker at the IFNHOS Meeting: Title: The oncogenic cross-talk between TP53 mutations and non-coding RNAs fuels relapse in HNSCC patients" Buenos Aires, September 3, 2018.
60. Invited Speaker at the 8th Mutp53 workshp. Title: Tracing and targeting TP53/PI3K mutations in HNSCC patients. Lyon, May 20, 2019.
61. Invited Speaker at TSCR conference on YAP/TAZ and TEAD: at the crossroad of cancer III.; Title: Novel insights in targeting YAP/TAZ in osteosarcoma. Telluride, June 12, 2019.
62. Special Guest Seminar Weizmann Institute of Science: Title: Tracing and targeting TP53/PI3K mutations in HNSCC patients. Rehovot, July 18, 2019.
63. Invited speaker at IAOO Meeting: Title: Targetable mutations in oral cancer. Rome, August 31- September 3, 2019.

64. Invited Seminar at the Univ. La Sapienza: Title: The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Rome, September 18, 2019.

Autorizzo il trattamento dei miei dati personali, ai sensi del D.lgs. 196 del 30 giugno 2003

Ai sensi degli artt. 46 e 47 del D.P.R. 445/2000 il sottoscritto Giovanni Blandino, sotto la propria personale responsabilità e consapevole che in caso di mendaci dichiarazioni incorrerà nelle pene stabilite dal codice penale e dalle leggi speciali in materia, ai sensi degli artt. 46 e 47 del D.P.R. 445/2000; consapevole delle sanzioni penali previste dall'art. 76 e delle conseguenze previste dall'art. 75 del medesimo D.P.R per le ipotesi di falsità in atti e dichiarazioni mendaci ivi indicate.

A

Roma, 18.06. 2020

